AU2016353539B2

AU2016353539B2 - Proenzyme composition

Info

Publication number: AU2016353539B2
Application number: AU2016353539A
Authority: AU
Inventors: Ralf Brandt; Julian Kenyon
Original assignee: Propanc Pty Ltd
Current assignee: Propanc Pty Ltd
Priority date: 2015-11-12
Filing date: 2016-11-11
Publication date: 2020-04-23
Anticipated expiration: 2036-11-11
Also published as: IL259259B2; ES2941348T3; JP2018533612A; IL259259A; WO2017079802A1; AU2016353539A1; EP3373956B1; EP3373956A4; MY196737A; IL259259B1; CA3003835A1; EP3373956A1; DK3373956T3; SG11201803531XA; NZ742020A; ZA201803855B; JP7479119B2; CN108367054A

Abstract

The present invention relates to compositions, methods, uses and kits for treating cancer. In particular, the invention relates to compositions and methods of treating cancer in a subject comprising administering chymotrypsinogen in certain amounts, for example greater than about 0.1mg/kg, and trypsinogen in an amount, for example, greater than about 0.02 mg/kg, thereby treating cancer. The invention also relate to compositions and methods for treating cancer in a subject comprising chymotrypsinogen and trypsinogen wherein the weight ratio of chymotrypsinogen : trypsinogen is greater than 8:1.

Description

Proenzyme composition

Cross references to related applications

The present application claims priority from Australian provisional application no. 2015904678 and US provisional no. 62/321377, the entire contents of both applications are hereby incorporated by reference in their entirety.

Field of the invention

The present invention relates to compositions, methods, uses and kits for treating cancer.

Background of the invention

The use of proteases in treating cancer has been suggested for some time. Initially fresh pancreatic enzyme extracts was contemplated as a possible cancer therapy and some successful experiments were conducted with Jersen's mouse sarcoma model. After injecting the mouse with the protease enzyme trypsin, a regression of tumours was observed. The results obtained produced great interest, and crude enzyme extracts prepared from sheep pancreas were used to treat human cancer patients to reduce tumour progression and prolong survival time.

The use of proenzymes (inactive precursor form of enzymes) has been used to try to overcome problems encountered with the oral administration of enzymes with mixed results. A proenzyme mixture including trypsinogen, which is the proenzyme form of the serine protease inhibitor trypsin, has been shown to be useful in treating carcinomas and believed to be selectively activated at the surface of tumour cells. The mechanism of action of trypsin is believed to occur by way of proteolysis of the tumour cells. A composition including chymotrypsinogen and trypsinogen has been shown to be effective in assays for cancer, including pancreatic cancer and colon cancer (WO 2011/047434).

However, there exists a need to provide new or improved cancer treatments.

Reference to any prior art in the specification is not an acknowledgment or suggestion that this prior art forms part of the common general knowledge in any

WO 2017/079802

PCT/AU2016/051082 jurisdiction or that this prior art could reasonably be expected to be understood, regarded as relevant, and/or combined with other pieces of prior art by a skilled person in the art.

Summary of the invention

The present invention provides a composition for treating cancer comprising chymotrypsinogen, trypsinogen and a pharmaceutically acceptable diluent, excipient or carrier, wherein the composition is adapted to administer chymotrypsinogen in an amount of equal to, or greater than, 0.1mg/kg and trypsinogen in an amount of equal to, or greater than, 0.02 mg/kg.

The invention also provides a composition for treating cancer in a subject comprising chymotrypsinogen and trypsinogen wherein the composition comprises chymotrypsinogen in an amount of greater than 1 mg/kg and trypsinogen in an amount of greater than 0.2 mg/kg.

In any aspect of the invention, the composition comprises or consists of chymotrypsinogen and trypsinogen, wherein the amount of chymotrypsinogen is greater than 1.5mg/kg, 2mg/kg, 3.5mg/kg, 5mg/kg, 15mg/kg, 20mg/kg, 40mg/kg, 45mg/kg, 135mg/kg, 250mg/kg or 500mg/kg. The amount of chymotrypsinogen and trypsinogen may be equal to, or greater than, any mg/kg value described herein, including in Tables 1,4, 8, 10 and the Examples, particularly Example 5.

In any aspect of the invention, the composition for treating cancer in a human comprises or consists of chymotrypsinogen and trypsinogen, wherein the amount of chymotrypsinogen is greater than 0.1 mg/kg, 0.15mg/kg, 0.25mg/kg, 0.4mg/kg, 1.2mg/kg, 3.5mg/kg, 10mg/kg, 20mg/kg or 40 mg/kg. The amount of chymotrypsinogen and trypsinogen may be equal to, or greater than, any mg/kg value described herein, particularly Example 5.

In any aspect of the invention, the composition comprises or consists of chymotrypsinogen and trypsinogen, wherein the amount of trypsinogen is greater than 0.25 mg/kg, 0.4mg/kg, 0.6 mg/kg, 0.8mg/kg, 2mg/kg, 2.5mg/kg, 3mg/kg, 5mg/kg, 7mg/kg, 8mg/kg, 20 mg/kg, 40mg/kg or 80mg/kg. The amount of chymotrypsinogen and

WO 2017/079802

PCT/AU2016/051082 trypsinogen may be equal to, or greater than, any mg/kg value described herein, including in Tables 1,4, 8, 10 and the Examples, particularly Example 5.

In any aspect of the invention, the composition for treating cancer in a human comprises or consists of chymotrypsinogen and trypsinogen, wherein the amount of trypsinogen is greater than 0.02mg/kg, 0.03mg/kg, 0.05mg/kg, 0.06mg/kg, 0.2mg/kg, 0.6mg/kg, 1.5mg/kg, 3mg/kg or 6mg/kg. The amount of chymotrypsinogen and trypsinogen may be equal to, or greater than, any mg/kg value described herein, particularly Example 5.

The invention provides a pharmaceutical composition for treating cancer in a subject comprising chymotrypsinogen, trypsinogen and a pharmaceutically acceptable diluent, excipient or carrier, wherein the composition comprises chymotrypsinogen in an amount of greater than 1 mg/kg and trypsinogen in an amount of greater than 0.2 mg/kg, or any other amount as described herein, particularly Example 5. In one embodiment, the only active anti-tumour ingredients present in the composition are chymotrypsinogen and trypsinogen.

The invention provides a pharmaceutical composition for treating cancer in a subject comprising as active ingredients chymotrypsinogen and trypsinogen, the composition further comprising a pharmaceutically acceptable diluent, excipient or carrier, wherein the composition comprises chymotrypsinogen in an amount of greater than 1 mg/kg and trypsinogen in an amount of greater than 0.2 mg/kg, or any other amount as described herein, particularly Example 5. In one embodiment, the only active anti-tumour ingredients present in the composition are chymotrypsinogen and trypsinogen.

The invention provides a pharmaceutical composition for treating cancer in a subject comprising as main ingredients chymotrypsinogen and trypsinogen, the composition further comprising a pharmaceutically acceptable diluent, excipient or carrier, wherein the composition comprises chymotrypsinogen in an amount of greater than 1 mg/kg and trypsinogen in an amount of greater than 0.2 mg/kg, or any other amount as described herein, particularly Example 5. In one embodiment, the only active anti-tumour ingredients present in the composition are chymotrypsinogen and trypsinogen.

WO 2017/079802

PCT/AU2016/051082

The invention provides a pharmaceutical composition for treating pancreatic cancer in a subject comprising chymotrypsinogen, trypsinogen and a pharmaceutically acceptable diluent, excipient or carrier, wherein the composition comprises chymotrypsinogen in an amount of at least greater than 10mg/kg, preferably greater than 13mg/kg, and trypsinogen in an amount of greater than 1.5mg/kg, preferably greater than 2mg/kg. Preferably, chymotrypsinogen in an amount of, or no more than, 41 mg/kg and trypsinogen in an amount of, or no more than, 7mg/kg.

The invention provides a pharmaceutical composition for treating ovarian cancer in a subject comprising chymotrypsinogen, trypsinogen and a pharmaceutically acceptable diluent, excipient or carrier, wherein the composition comprises chymotrypsinogen in an amount of greater than 3mg/kg, preferably greater than 4mg/kg, and trypsinogen in an amount of greater than 0.4mg/kg, preferably greater than 0.7mg/kg. Preferably, chymotrypsinogen in an amount of, or no more than, 13mg/kg and trypsinogen in an amount of, or no more than, 2.2mg/kg.

The invention also provides a pharmaceutical composition for use in treating cancer in a subject comprising chymotrypsinogen, trypsinogen and a pharmaceutically acceptable diluent, excipient or carrier, wherein the composition comprises chymotrypsinogen in an amount of greater than 1mg/kg and trypsinogen in an amount of greater than 0.2 mg/kg, or any other amount as described herein, particularly Example 5.

The invention also provides a pharmaceutical composition comprising chymotrypsinogen, trypsinogen and a pharmaceutically acceptable diluent, excipient or carrier for use in treating cancer in a subject, wherein the composition comprises chymotrypsinogen in an amount of greater than 1 mg/kg and trypsinogen in an amount of greater than 0.2 mg/kg, or any other amount as described herein, particularly Example 5.

The present invention also provides a unit dose composition comprising chymotrypsinogen and trypsinogen, wherein the unit dose is adapted to administer chymotrypsinogen in an amount of greater than, or equal to, 6mg/kg and trypsinogen in an amount of greater than, or equal to, 1 mg, or any other amount as described herein. Preferably, chymotrypsinogen is in an amount of greater than, or equal to, 9mg, 15mg,

WO 2017/079802

PCT/AU2016/051082

24mg, 72mg, 210mg, 600mg, 1200mg, 2400mg. Preferably, trypsinogen is in an amount of greater than or equal to 1.5mg, 3mg, 3.5mg, 12 mg, 36mg, 90mg, 180mg or 360mg.

The present invention also provides a composition for use in treating cancer, the composition comprising trypsinogen at a concentration of 0.25mg/ml and chymotrypsinogen at a concentration of 1.5 mg/ml. Preferably, trypsinogen is in a concentration of 4.3, 8.7 or 30 mg/ml and chymotrypsinogen is in a concentration of 25, 50 or 100mg/ml. Trypsinogen and chymotrypsinogen may be in any other concentration as described herein such as those in the Examples.

In any aspect of the invention, the pharmaceutical composition comprises, consists of, or is adapted to administer, chymotrypsinogen and trypsinogen, wherein the amount of chymotrypsinogen is greater than 1.5mg/kg, 2mg/kg, 3.5mg/kg, 5mg/kg, 15mg/kg, 20mg/kg, 40mg/kg, 45mg/kg, 135mg/kg, 250mg/kg or 500mg/kg. The amount of chymotrypsinogen and trypsinogen may be equal to, or greater than, any mg/kg value described herein, including in Tables 1,4, 8, 10 and the Examples, particularly Example

5.

In any aspect of the invention, the pharmaceutical composition for human use comprises, consists of, or is adapted to administer chymotrypsinogen and trypsinogen, wherein the amount of chymotrypsinogen is greater than 0.1 mg/kg, 0.15mg/kg, 0.25mg/kg, 0.4mg/kg, 1.2mg/kg, 3.5mg/kg, 10mg/kg, 20mg/kg or 40 mg/kg. The amount of chymotrypsinogen may be equal to, or greater than, any mg/kg value described herein, particularly Example 5.

In any aspect of the invention, the pharmaceutical composition comprises, consists of, or is adapted to administer, chymotrypsinogen and trypsinogen, wherein the amount of trypsinogen administered is greater than 0.25 mg/kg, 0.4mg/kg, 0.6 mg/kg, 0.8mg/kg, 2mg/kg, 2.5mg/kg, 3mg/kg, 5mg/kg, 7mg/kg, 8mg/kg, 20 mg/kg, 40mg/kg or 80mg/kg. The amount of trypsinogen may be equal to, or greater than, any mg/kg value described herein, including in Tables 1, 4, 8, 10 and the Examples.

In any aspect of the invention, the pharmaceutical composition for human use comprises, consists of, or is adapted to administer chymotrypsinogen and trypsinogen,

WO 2017/079802

PCT/AU2016/051082 wherein the amount of trypsinogen administered is greater than 0.02mg/kg, 0.03mg/kg, 0.05mg/kg, 0.06mg/kg, 0.2mg/kg, 0.6mg/kg, 1.5mg/kg, 3mg/kg or 6mg/kg. The amount of trypsinogen may be equal to, or greater than, any mg/kg value described herein, particularly Example 5.

The present invention includes a method of treating cancer in a subject comprising administering chymotrypsinogen in an amount of greater than 1 mg/kg and trypsinogen in an amount of greater than 0.2 mg/kg, thereby treating cancer.

In any method of the invention, the amount of chymotrypsinogen administered in a single dose or in multiple doses over the period of a 24 hour period is greater than 1 mg/kg but less than 500 mg/kg.

In any method of the invention, the amount of trypsinogen administered in a single dose or in multiple doses over the period of a 24 hour period is at least greater than 0.2 mg/kg but less than 90 mg/kg.

The present invention provides a method of treating cancer in a subject comprising administering chymotrypsinogen in an amount of 500mg/kg and trypsinogen in an amount of 83 mg/kg, thereby treating cancer. Preferably, the cancer is pancreatic cancer or ovarian cancer. Even more preferably, the pancreatic cancer is an adenocarcinoma.

The present invention provides a method of treating cancer in a human comprising administering chymotrypsinogen in an amount of 40mg/kg and trypsinogen in an amount of 7mg/kg, thereby treating cancer. Preferably, the cancer is pancreatic cancer. Even more preferably, the pancreatic cancer is an adenocarcinoma.

The present invention provides a method of treating cancer in a human comprising administering chymotrypsinogen in an amount of 4mg/kg or 13mg/kg and trypsinogen in an amount of 0.7mg/kg or 2mg/kg, thereby treating cancer. Preferably, the cancer is ovarian cancer.

In any method of the invention, the administration of the amount of trypsinogen and chymotrypsinogen does not result in any clinically observable adverse event in the subject 1 week after administration, 1 day after administration, or preferably 1 hour after

WO 2017/079802

PCT/AU2016/051082 administration. The clinically observable adverse event may be any one or more of weight loss, reddening at site of injection and behavioural changes, or any other event described herein, particularly the Examples.

In any aspect of the invention, chymotrypsinogen and trypsinogen is administered in a weight ratio in the range of at or about 1 : 1 to at or about 10 : 1, at or about 4 : 1 to at or about 8 : 1, at or about 5 : 1 to at or about 7 : 1, or at about 6 : 1. Further, any composition described above has chymotrypsinogen and trypsinogen in a weight ratio in the range of at or about 1 : 1 to at or about 10 : 1, at or about 4 : 1 to at or about 8 : 1, at or about 5 : 1 to at or about 7 : 1, or at about 6 : 1

The present invention also provides use of chymotrypsinogen and trypsinogen in the manufacture of a medicament for the treatment of cancer, wherein the medicament is adapted to administer chymotrypsinogen in an amount of greater than 1mg/kg and trypsinogen in an amount of greater than 0.2 mg/kg, or any other amount as described herein, particularly Example 5.

The invention also provides a kit for treating cancer comprising at least one dosage unit, wherein the dosage unit comprises chymotrypsinogen, trypsinogen and a pharmaceutically acceptable diluent, excipient or carrier, wherein the dosage unit is adapted to administer chymotrypsinogen and trypsinogen equal to, or greater than, any amount or mg/kg value described herein, including in Tables 1, 4, 8 and 10, particularly Example 5.

Optionally the kit also includes written instructions directing the user to administer a dosage unit of chymotrypsinogen in an amount of greater than 1 mg/kg and trypsinogen in an amount of greater than 0.2 mg/kg, or any other amount as described herein, particularly Example 5.

The methods and pharmaceutical compositions of the invention are useful for treating cancers and metastatic carcinomas including pancreatic cancer, oesophageal cancer, colon cancer, bowel cancer, prostate cancer, ovarian cancer, brain cancer, stomach cancer, breast cancer, liver cancer, malignant melanoma or lung cancer. Preferably, the cancer is pancreatic cancer, colon cancer or ovarian cancer. More preferably, the cancer is pancreatic cancer.

WO 2017/079802

PCT/AU2016/051082

In any aspect of a method or use of the invention, the method or use further comprises the step of identifying a subject having, or at risk of developing, cancer. Preferably, the cancer is any one described herein.

In any aspect of the invention, the composition does not contain or the method or use does not administer, amylase.

In any aspect, embodiment or form of the invention described herein the amount of chymotrypsinogen administered may be greater than, or equal to, 1mg/kg, 1.5mg/kg, 2mg/kg, 3.5mg/kg, 5mg/kg, 15mg/kg, 20mg/kg, 40mg/kg, 45mg/kg, 135mg/kg, 250mg/kg or 500mg/kg. The chymotrypsinogen administered may be equal to, or greater than, any mg/kg value described herein, including in Tables 1, 4, 8 and 10, particularly Example 5.

In any aspect, embodiment or form of the invention described herein the amount of trypsinogen administered may be greater than, or equal to, 0.2mg/kg, 0.25 mg/kg, 0.4mg/kg, 0.6 mg/kg, 0.8mg/kg, 2mg/kg, 2.5mg/kg, 3mg/kg, 5mg/kg, 7mg/kg, 8mg/kg, 20 mg/kg, 40mg/kg or 80mg/kg. The trypsinogen administered may be equal to, or greater than, any mg/kg value described herein, including in Tables 1, 4, 8 and 10, particularly Example 5.

In any aspect, embodiment or form of the invention described herein the amount of chymotrypsinogen administered to a human may be greater than, or equal to, 0.1 mg/kg, 0.15mg/kg, 0.25mg/kg, 0.4mg/kg, 1.2mg/kg, 3.5mg/kg, 10mg/kg, 20mg/kg or mg/kg. The amount of chymotrypsinogen may be equal to, or greater than, any mg/kg value described herein, particularly Example 5.

In any aspect, embodiment or form of the invention described herein the amount of trypsinogen administered to a human may be greater than, or equal to, 0.02mg/kg, 0.03mg/kg, 0.05mg/kg, 0.06mg/kg, 0.2mg/kg, 0.6mg/kg, 1.5mg/kg, 3mg/kg or 6mg/kg. The amount of trypsinogen may be equal to, or greater than, any mg/kg value described herein, particularly Example 5.

Preferably, in any aspect, embodiment or form of the invention described herein the amount of chymotrypsinogen administered may be in the range of 1 mg/kg to mg/kg, 1.5mg/kg to 500mg/kg, 2mg/kg to 250mg/kg, 3.5mg/kg to 135mg/kg, 5mg/kg

WO 2017/079802

PCT/AU2016/051082 or 15mg/kg to 45mg/kg. The chymotrypsinogen administered may be in a range of between any two mg/kg values described herein, including in Tables 1, 4, 8, 10 and the Examples, particularly Example 5.

Preferably, in any aspect, embodiment or form of the invention described herein the amount of trypsinogen administered may be greater than 0.2mg/kg to 7mg/kg, 0.25 mg/kg to 80mg/kg, 0.4mg/kg to 40mg/kg, 0.6 mg/kg to 20 mg/kg, 0.8mg/kg to 8mg/kg, or 2.5mg/kg to 8mg/kg. The trypsinogen administered may be in a range of between any two mg/kg values described herein, including in Tables 1, 4, 8, 10 and the Examples, particularly Example 5.

In any composition of the invention above, the composition may be adapted to administer the relevant mg, or mg/kg, of chymotrypsinogen and trypsinogen to the subject.

The invention also provides, any aspect of the invention above including values are ‘about’ the stated value above. For example, a further aspect of the invention is any of the aspects above where reference to 500mg/kg is about 500mg/kg. This is contemplated for all aspects or embodiments of the invention and for all values.

The invention provides a composition for treating cancer in a subject comprising chymotrypsinogen and trypsinogen wherein the weight ratio of chymotrypsinogen : trypsinogen is greater than 8:1 (i.e. 8 or more : 1). Preferably, the weight ratio is greater than 10:1. Preferably, the weight ratio is 10:1. The weight ratio may be 8:1, 10:1 or between 8: 1 and 10:1. In any of the embodiments, the composition preferably does not contain amylase, i.e. it comprises administration of an amylase-free composition..

The present invention provides a method of treating cancer in a subject comprising administering chymotrypsinogen and trypsinogen, wherein the weight ratio of chymotrypsinogen : trypsinogen is greater than 8:1, thereby treating cancer in the subject. Preferably, the weight ratio is greater than 10:1. Preferably, the weight ratio is 10:1. The weight ratio may be 8:1, 10:1 or between 8: 1 and 10:1. In one embodiment, the method does not comprise the administration of amylase, i.e. it comprises administration of an amylase-free composition.

WO 2017/079802

PCT/AU2016/051082

The present invention provides use of chymotrypsinogen and trypsinogen, in the manufacture of a medicament for the treatment of cancer, wherein the weight ratio of chymotrypsinogen : trypsinogen is greater than 8:1. Preferably, the weight ratio is greater than 10:1. Preferably, the weight ratio is 10:1. The weight ratio may be 8:1, 10:1 or between 8: 1 and 10:1. In one embodiment, the medicament does not comprise amylase.

Preferably, the cancer is any one or more of pancreatic cancer, oesophageal cancer, colon cancer, bowel cancer, prostate cancer, ovarian cancer, stomach cancer, breast cancer, liver cancer, malignant melanoma, fibrosarcoma or lung cancer. Preferably, the cancer is ovarian, melanoma, brain, prostate, colorectal, liver or lung. Preferably, the cancer is pancreatic cancer, colon cancer or ovarian cancer. More preferably, the cancer is pancreatic cancer.

In any aspect of the invention, chymotrypsinogen and trypsinogen is administered intravenously, subcutaneously or intramuscularly.

In any aspect of the invention, chymotrypsinogen and trypsinogen may be administered simultaneously or sequentially.

As used herein, except where the context requires otherwise, the term comprise and variations of the term, such as comprising, comprises and comprised, are not intended to exclude further additives, components, integers or steps.

Further aspects of the present invention and further embodiments of the aspects described in the preceding paragraphs will become apparent from the following description, given by way of example and with reference to the accompanying drawings.

Brief description of the drawings

Figure 1: Mean Body Weight ± SEM (g) for Each Group During Study # 1. Treatments were administered as single i.v. injection, once daily for seven consecutive days. Treatment was initiated to each group in a staggered manner, beginning with the lowest dose and then increasing the dose on each subsequent day. For all data

WO 2017/079802

PCT/AU2016/051082 calculations and presentation, the first day of treatment for each group is designated as Study Day 0.

Figure 2: Mean Body Weight ± SEM (g) for Each Group During Study #2. Treatments were administered as single i.v. injection, once daily for seven consecutive days. Treatment was initiated to each group in a staggered manner, beginning with the lowest dose on the first day and then increasing the dose to Trypsinogen/Chymotrypsinogen A at 86.8/500 mg/kg on the second day. Treatment with Trypsinogen/Chymotrypsinogen A at 43.4/250 mg/kg commenced on the third day. For all data calculations and presentation, the first day of treatment for each group is designated as Study Day 0.

Figure 3: Results of mean tumour weight ± SEM (mg) of PBS control mice (Group 1, n=8) and mice receiving T:C, 27.5 mg/kg: 165 mg/kg (Group 2, n=9) or T:C, 83.3 mg/kg:500 mg/kg (Group 3, n=10) in study described in Example 3 performed to assess anti-tumour efficacy of Trypsinogen and Chymotrypsinogen A, administered in combination against Pan02 mouse pancreatic cancer cells, orthotopically inoculated in female C57BL/6 mice. Treatments were administered as single i.v. injection, one daily on Study Days 0 to 25. Animals were terminated on Study Day 26.

Figure 4: Images of excised tumours from mice in Group 1 (PBS, 10 ml/kg, daily i.v) Day 26 in study described in Example 3 performed to assess anti-tumour efficacy of Trypsinogen and Chymotrypsinogen A, administered in combination against Pan02 mouse pancreatic cancer cells, orthotopically inoculated in female C57BL/6 mice.

Figure 5: Images of excised tumours from mice in Group 2 (T:C, 27.5 mg/kg: 165 mg/kg) Day 26 in study described in Example 3 performed to assess anti-tumour efficacy of Trypsinogen and Chymotrypsinogen A, administered in combination against Pan02 mouse pancreatic cancer cells, orthotopically inoculated in female C57BL/6 mice.

Figure 6: Images of excised tumours from mice in Group 3 (T:C, 83.3 mg/kg:500 mg/kg) Day 26 in study described in Example 3 performed to assess anti-tumour efficacy of Trypsinogen and Chymotrypsinogen A, administered in combination against

WO 2017/079802

PCT/AU2016/051082

Pan02 mouse pancreatic cancer cells, orthotopically inoculated in female C57BL/6 mice.

Figure 7: Mean Tumour Weight ± SEM (g) in Group 2: Vehicle Control (PBS). Group 3: Trypsinogen/Chymotrypsinogen A, 83.3/500 mg/kg. Group 4: Trypsinogen/Chymotrypsinogen A, 27.5/165 mg/kg. Group 5: Trypsinogen/Chymotrypsinogen A, 9.1/54 mg/kg, in study described in Example 4 performed to assess anti-tumour efficacy of Trypsinogen and Chymotrypsinogen A, administered in combination, against A2780 human ovarian cancer cells orthotopically inoculated in female Athymic Nude-Fox/?/™ mice. Treatments were administered as a single i.v. injection, once daily (Study Days 0 to 20). These animals were terminated on Study Day 21.

Figure 8: Images of excised tumours at study termination for Group 2: Vehicle Control (PBS) in study described in Example 4 performed to assess anti-tumour efficacy of Trypsinogen and Chymotrypsinogen A, administered in combination, against A2780 human ovarian cancer cells orthotopically inoculated in female Athymic Nude-Fox/?/™ mice.

Figure 9: Images of excised tumours at study termination for Group 3: Trypsinogen/Chymotrypsinogen A, 83.3/500 mg/kg in study described in Example 4 performed to assess anti-tumour efficacy of Trypsinogen and Chymotrypsinogen A, administered in combination, against A2780 human ovarian cancer cells orthotopically inoculated in female Athymic Nude-Fox/?/™ mice.

Figure 10: Images of excised tumours at study termination for Group 4: Trypsinogen/Chymotrypsinogen A, 27.5/165 mg/kg in study described in Example 4 performed to assess anti-tumour efficacy of Trypsinogen and Chymotrypsinogen A, administered in combination, against A2780 human ovarian cancer cells orthotopically inoculated in female Athymic Nude-Fox/?/™ mice.

Figure 11: Images of excised tumours at study termination for Group 5: Trypsinogen/Chymotrypsinogen A, 9.1/54 mg/kg in study described in Example 4 performed to assess anti-tumour efficacy of Trypsinogen and Chymotrypsinogen A,

WO 2017/079802

PCT/AU2016/051082 administered in combination, against A2780 human ovarian cancer cells orthotopically inoculated in female Athymic Nude-Foxn/™ mice.

Figure 12: The effect of Trypsinogen and Chymotrypsinogen alone or in combination on the growth of A2780 human ovary tumour cells. Combination assays of Trypsinogen and Chymotrypsinogen were performed at ratios of 1:1, 1:2, 1:4, 1:6, 1:8 and 1:10 based on the previously determined IC50 of Trypsinogen (3.174mg/ml). CDI values were calculated as described.

Figure 13: The effect of Trypsinogen and Chymotrypsinogen alone or in combination on the growth of C8161.9 human melanoma cells. Combination assays of Trypsinogen and Chymotrypsinogen were performed at ratios of 1:1, 1:2, 1:4, 1:6, 1:8 and 1:10 based on the previously determined IC50 of Trypsinogen (3.917mg/ml). CDI values were calculated as described.

Figure 14: The effect of Trypsinogen and Chymotrypsinogen alone or in combination on the growth of DAOY human brain tumour cells. Combination assays of Trypsinogen and Chymotrypsinogen were performed at ratios of 1:1, 1:2, 1:4, 1:6, 1:8 and 1:10 based on the previously determined IC50 of Trypsinogen (2.654mg/ml). CDI values were calculated as described.

Figure 15: The effect of Trypsinogen and Chymotrypsinogen alone or in combination on the growth of DLI145 human prostate tumour cells. Combination assays of Trypsinogen and Chymotrypsinogen were performed at ratios of 1:1, 1:2, 1:4, 1:6, 1:8 and 1:10 based on the previously determined IC50 of Trypsinogen (3.843mg/ml). CDI values were calculated as described.

Figure 16: The effect of Trypsinogen and Chymotrypsinogen alone or in combination on the growth of HCT 116 human colorectal tumour cells. Combination assays of Trypsinogen and Chymotrypsinogen were performed at ratios of 1:1, 1:2, 1:4, 1:6, 1:8 and 1:10 based on the previously determined IC50 of Trypsinogen (16.43mg/ml). CDI values were calculated as described.

Figure 17: The effect of Trypsinogen and Chymotrypsinogen alone or in combination on the growth of Hep3B2.1-7 human liver tumour cells. Combination assays of Trypsinogen and Chymotrypsinogen were performed at ratios of 1:1, 1:2, 1:4,

WO 2017/079802

PCT/AU2016/051082

1:6, 1:8 and 1:10 based on the previously determined ICso of Trypsinogen (2.483mg/ml). CD I values were calculated as described.

Figure 18: The effect of Trypsinogen and Chymotrypsinogen alone or in combination on the growth of HT-29 human colorectal tumour cells. Combination assays of Trypsinogen and Chymotrypsinogen were performed at ratios of 1:1, 1:2, 1:4, 1:6, 1:8 and 1:10 based on the previously determined ICso of Trypsinogen (15.12mg/ml). CD I values were calculated as described.

Figure 19: The effect of Trypsinogen and Chymotrypsinogen alone or in combination on the growth of HuH-7 human liver tumour cells. Combination assays of Trypsinogen and Chymotrypsinogen were performed at ratios of 1:1, 1:2, 1:4, 1:6, 1:8 and 1:10 based on the previously determined ICso of Trypsinogen (3.934mg/ml). CDI values were calculated as described.

Figure 20: The effect of Trypsinogen and Chymotrypsinogen alone or in combination on the growth of NCI-H460 human lung tumour cells. Combination assays of Trypsinogen and Chymotrypsinogen were performed at ratios of 1:1, 1:2, 1:4, 1:6, 1:8 and 1:10 based on the previously determined ICso of Trypsinogen (4.028mg/ml). CDI values were calculated as described.

Detailed description of the embodiments

It will be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the individual features mentioned or evident from the text or drawings. All of these different combinations constitute various alternative aspects of the invention.

Reference will now be made in detail to certain embodiments of the invention. While the invention will be described in conjunction with the embodiments, it will be understood that the intention is not to limit the invention to those embodiments. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents, which may be included within the scope of the present invention as defined by the claims.

WO 2017/079802

PCT/AU2016/051082

One skilled in the art will recognize many methods and materials similar or equivalent to those described herein, which could be used in the practice of the present invention. The present invention is in no way limited to the methods and materials described. It will be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the individual features mentioned or evident from the text or drawings. All of these different combinations constitute various alternative aspects of the invention.

All of the patents and publications referred to herein are incorporated by reference in their entirety.

For purposes of interpreting this specification, terms used in the singular will also include the plural and vice versa.

The present invention is based on the surprising finding that chymotrypsinogen and trypsinogen can be administered at amounts significantly higher than previously used. This could occur in a single administration, or over a period of a single day. Surprisingly, these significantly higher amounts of chymotrypsinogen and trypsinogen, even hundred fold higher amounts, can be administered without any significant adverse clinical events. In addition, these higher amounts are shown to reduce the weight of several tumour types in vivo. The present invention provides an important benefit in the treatment of cancer as a larger effective dose of chymotrypsinogen and trypsinogen can be safely administered than previously used thereby providing a greater therapeutic window.

Chymotrypsinogen (which may be abbreviated to ‘C’ herein) is a proenzyme form of the enzyme chymotrypsin, which preferentially cleaves proteins at the following amino acids: tyrosine, tryptophan, phenylalanine and leucine. Chymotrypsin may be referred to or includes chymotrypsin A, chymotrypsin B (including B1 and B2 forms), chymotrypsin C, a-chymarophth, avazyme, chymar, chymotest, enzeon, quimar, quimotrase, a-chymar, α-chymotrypsin A, a-chymotrypsin. Chymotrypsin C can be formed from pig chymotrypsinogen C or from cattle subunit II of procarboxypeptidase A, and preferentially cleaves proteins at the following amino acids: tyrosine, tryptophan, phenylalanine, leucine, methionine, glutamine, and asparagine. Chymotrypsinogen includes chymotrypsinogen B1 and chymotrypsinogen B2.

WO 2017/079802

PCT/AU2016/051082

Trypsinogen (which may be abbreviated to T herein) is a proenzyme form of trypsin, which preferentially cleaves proteins at arginine and lysine. Trypsin may be referred to or include a-trypsin, β-trypsin, cocoonase, parenzyme, parenzymol, tryptar, trypure, pseudotrypsin, tryptase, tripcellim, sperm receptor hydrolase β-trypsin can be formed from trypsinogen by cleavage of one peptide bond. Further peptide bond cleavages produce a and other iso-forms. Multiple cationic and anionic trypsins can be isolated from the pancreas of many vertebrates and from lower species including crayfish, insects (cocoonase) and microorganisms (Streptomyces griseus). In normal processes during digestion, inactive trypsinogen is activated by enteropeptidase present in intestinal mucosa to form the enzyme trypsin, which being a serine protease then acts to cleave the peptide bonds on the carboxyl side of basic amino acids/proteins.

The trypsinogen and chymotrypsinogen used in any aspect of the invention may be isolated, purified, substantially purified, recombinant or synthetic.

The proenzymes trypsinogen and chymotrypsinogen may be precursors of the enzymes selected from chymotrypsin classes 3.4.21.1 or 3.4.21.2 or trypsin from class 3.4.21.4, or selected from any other suitable source (classes grouped according to the classification of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology). These enzymes are commercially available and may be of human, bovine or porcine origin.

As used herein, “any other amount as described herein” or “any mg/kg value described herein” includes any amount or mg/kg value described in any of the Examples including in Tables 1,4, 8 and 10.

The present invention includes human conversions for all amounts in mg/kg referred to herein based on human body weights of 50, 60, 70, 80, 90, 100 or more kg and body surface area of 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8 or more m². Specifically, amounts per kg for human administration, and methods for calculation, are referred to in Example 5.

As mentioned, the proenzyme form essentially provides an inactivated form of the enzyme that becomes activated in situ (e.g in vivo or in vitro activation). For example, activation of the proenzyme (conversion of proenzyme to active enzyme) may

WO 2017/079802

PCT/AU2016/051082 occur on contact with the surface of the tumour cell. It is believed that the proenzymes trypsinogen and chymotrypsinogen are selectively activated into the enzymes trypsin and chymotrypsin on contact with tumour cells and not on contact with healthy cells. The use of proenzymes reduces problems associated with providing, in situ, an active enzyme, such as undesirable reactions or inactivation of the enzyme before reaching an intended target of a tumour cell.

In relation to tumour cells, protease enzymes can act to break down the cell wall of malignant cells by cleaving the amide bonds present in peptide chains of the cell walls (proteolysis). It is also understood that protease inhibitors, which are present in non-malignant cells and inhibit or reduce the effect of enzymes in breaking down cell walls, are absent in malignant tumour cells. In addition to providing proteolytic activity, the protease proenzymes can upregulate the expression of β-catenin and E-cadherin in tumour cells. Cell-to-cell adhesion is facilitated by complex formation or bonding between β-catenin and E-cadherin at the cell surface, and therefore increased expression of β-catenin and E-cadherin leads to enhanced cell-to-cell adhesion and thereby reducing metastasis of tumour cells. The protease proenzymes may also provide other cellular activity such as increased immunorecognition or differentiation.

A significant adverse event, experience or reaction is any untoward medical occurrence that at any dose: results in death, is life-threatening (places the subject at immediate risk of death), requires in subject/subject hospitalization or prolongation of existing hospitalization, results in persistent or significant disability, incapacity, or is a congenital anomaly/birth defect.

A clinically observable adverse event is any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product. A clinically observable adverse event may include any one of the events or observations described herein, particularly in the Examples. Typically, the period of observation is about 1 week after administration, about 1 day after administration, or preferably about 1 hour after administration. The period of observation may be the time between administration of doses.

WO 2017/079802

PCT/AU2016/051082

Treating or treatment refers to both therapeutic treatment and prophylactic or preventative measures, wherein the aim is to prevent, ameliorate, reduce or slow down (lessen) cancer or the spread (metastasis) thereof.

In any method of the invention, one or more of the following effects may be observed: reduction in the reoccurrence of malignant tumours, reduction in metastasis of malignant tumours, reduction in number or size of tumours, differentiation of tumour cells, expression of β-catenin and E-cadhehn in malignant tumours to facilitate cell-tocell adhesion and reduction in metastasis, reduction in tumour cells ability to prevent immunorecognition.

Preventing, prevention, preventative or prophylactic refers to keeping from occurring, or to hinder, defend from, or protect from the occurrence of a condition, disease, disorder, or phenotype, including an abnormality or symptom. A subject in need of prevention may be prone to develop the condition.

The term ameliorate or amelioration refers to a decrease, reduction or elimination of a condition, disease, disorder, or phenotype, including an abnormality or symptom. A subject in need of treatment may already have the condition, or may be prone to have the condition or may be one in whom the condition is to be prevented.

The subject includes a mammal. The mammal may be a human, or may be a domestic, zoo, or companion animal. While it is particularly contemplated that the methods of the invention are suitable for medical treatment of humans, they are also applicable to veterinary treatment, including treatment of companion animals such as dogs and cats, and domestic animals such as horses, cattle and sheep, or zoo animals such as felids, canids, bovids, and ungulates. A subject may be afflicted with cancer or other disorder, or may not be afflicted with cancer or other disorder (i.e., free of detectable disease).

The typical body weight of a human subject may be greater than, or equal to, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105 or 11 Okg.

The term therapeutically effective amount refers to an amount of composition, or agent or compound in the composition, capable of treating, preventing or ameliorating cancer or the spread (metastasis) thereof. A therapeutically effective

WO 2017/079802

PCT/AU2016/051082 amount may be determined empirically and in a routine manner in relation to treating cancer, and will result in increased life expectancy.

As used herein “adapted to administer” refers to a composition that has the capacity to administer trypsinogen and chymotrypsinogen at the specified amount or concentration in a single dose or multiple doses.

As described herein, methods of the invention include treatment of neoplasms and related conditions, cancers, tumours, malignant and metastatic conditions. Tissues and organs associated with solid tumours and metastases which can be treated with a method or pharmaceutical composition of the invention include, but are not limited to, biliary tract, bladder, blood, brain, breast, cervix, colon, endometrium, esophagus, head, neck, kidney, larynx, liver, lung, medulla, melanin, ovarian, pancreas, prostate, rectum, renal, retina, skin, stomach, testes, thyroid, urinary tract, and uterus. The cancer may be a carcinoma and developed in an epithelium or from epithelial cells. The cancer may be a sarcoma and developed in connective tissue.

The methods and pharmaceutical compositions of the invention are useful for treating cancers and metastatic carcinomas of the following types: pancreatic cancer, oesophageal cancer, colon cancer, bowel cancer, prostate cancer, ovarian cancer, stomach cancer, breast cancer, malignant melanoma or lung cancer. Preferably, the cancer is pancreatic cancer, colon cancer or ovarian cancer. More preferably, the cancer is pancreatic cancer.

The methods and pharmaceutical compositions of the invention may provide a multiple effect approach to treating cancer, for example by increasing in tumour cells apoptosis, cell-to-cell adhesion, differentiation and immunogenicity (targeting and removal by immune system). It is therefore beneficial to conduct treatment in the absence of any other treatments that may suppress or harm the immune system.

Methods or uses of the invention can be supplemented by other conventional anti-cancer therapeutic approaches directed to treatment or prevention of proliferative disorders (e.g., tumour). For example, such methods can be used in prophylactic cancer prevention, prevention of cancer recurrence and metastases after surgery, and as an adjuvant of other conventional cancer therapy.

WO 2017/079802

PCT/AU2016/051082

The pharmaceutical compositions of the invention may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (for example, excipients, binders, preservatives, stabilizers, flavors, etc.) according to techniques such as those well known in the art of pharmaceutical formulation.

The pharmaceutical compositions of the invention may be administered by any suitable means, for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intracisternal injection or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents. They may, for example, be administered in a form suitable for immediate release or extended release, for example, by the use of devices such as subcutaneous implants, encapsulated spheroids or osmotic pumps.

In addition to primates, such as humans, a variety of other mammals can be treated according to the methods of the tenth aspect. For instance, mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent or murine species can be treated.

The term pharmaceutically acceptable as used herein means the carrier, diluent or excipient is not deleterious to the recipient thereof.

The terms administration of and or administering should be understood to mean providing to an individual in need of treatment.

An individual in need of treatment may be one diagnosed with, or at risk of developing, any one of the cancers described herein.

The pharmaceutical compositions of the invention, and preparations or formulations thereof may be prepared by admixing together the components of the composition, namely chymotrypsinogen and trypsinogen. The admixing may be performed sequentially or simultaneously.

WO 2017/079802

PCT/AU2016/051082

The pharmaceutical compositions of the invention may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active agents and protease proenzyme into association with the carrier which constitutes one or more accessory ingredients. In general, the pharmaceutical compositions are prepared by uniformly and intimately bringing the active agents and protease proenzymes into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. The active agents and protease proenzymes are provided in a dosage unit form in an amount sufficient to produce the desired effect upon the process or condition of diseases after single or repeated administration.

The pharmaceutical compositions of the invention may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the protease proenzyme and active agent of the first and second aspects in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard gelatin capsules wherein the protease proenzyme and active agent of the first and second aspects are

WO 2017/079802

PCT/AU2016/051082 mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the protease proenzyme and active agent of the first and second aspects are mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active agent and protease proenzyme in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxy-propylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, n-methyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

Oily suspensions may be formulated by suspending the active agent and protease proenzyme in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the protease proenzyme and active agent of the first and second aspects in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional

WO 2017/079802

PCT/AU2016/051082 excipients, for example sweetening, flavouring and colouring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of oilin-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally- occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxy ethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. They may also contain a demulcent, a preservative and flavoring and coloring agents.

The pharmaceutical compositions of invention may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The pharmaceutical compositions of the first and second aspects may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1 ,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

In a particular embodiment, the pharmaceutical compositions of the invention are formulated as suppositories for rectal administration of the drug. These formulations can be prepared by mixing the protease proenzyme and active agent of the first and second aspects with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the

WO 2017/079802

PCT/AU2016/051082 drug. Such materials include cocoa butter and polyethylene glycols. Rectal administration may be used to elimate entero-hepatic first pass effect in the gastrointestinal tract related to oral administration of enzymes.

The pharmaceutical compositions of the invention, may also be formulated in liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multilamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolisable lipid capable of forming liposomes can be used. The liposome formulation may contain stabilisers, preservatives, excipients and the like. The preferred lipids are the phospholipids and phosphatidyl cholines, both natural and synthetic. Methods to form liposomes are known in the art.

The pharmaceutical compositions of the invention, may be included in a container, pack, or dispenser together with instructions for administration. The protease proenzymes and active agents, and optionally additional active agent, of the pharmaceutical composition may be provided as separated components in the container, pack, or dispenser, to be taken separately or together at the same or different time in a use or method of the invention described herein.

Examples

Example 1

A dosing study was completed to determine the maximum tolerated and feasible dose in which no adverse clinical events were observed, or in which any adverse clinical events were resolved by the subsequent dosing. The dosing study protocol is set out below.

Trypsinogen and Chymotrypsinogen A were dissolved in phosphate buffered saline (PBS) on each treatment day to give stock solutions of 1 mg/mL. Dosing

WO 2017/079802

PCT/AU2016/051082 solutions of the required concentrations of Trypsinogen/Chymotrypsinogen A were prepared by diluting the stock solutions together in PBS to achieve the desired final concentration of each.

For Study #1, dosing solutions of Trypsinogen/Chymotrypsinogen A at 0.0254/0.1521, 0.0381/0.2282, 0.0572/0.3423 and 0.0858/0.5135 mg/mL were prepared.

For the study, treatments were administered to animals in each group once daily for seven consecutive days in a dosing volume of 10 mL/kg. The volume of dosing solution administered to each animal was calculated and adjusted based on individual body weight measured immediately prior to dosing.

For Study #1 mice were randomised by body weight into four groups of four mice. The dosing regimen used for the study is summarised in Table 1. Trypsinogen and Chymotrypsinogen A were administered in combination as a single intravenous tail vein injection (i.v.) at doses of 10 mL/Kg. The final concentration of Trypsinogen and Chymotrypsinogen for each group were 0.254/1.521,0.381/2.282, 0.572/3.423 and 0.858/5.135 mg/kg (Groups 1,2, 3 and 4, respectively).

Treatment for each group in Study #1 was initiated in a staggered manner, beginning with the lowest dose of Trypsinogen/Chymotrypsinogen A, and then increasing the dose on each subsequent study day. For all data calculations and presentation, the first day of treatment for each group is designated as Study Day 0.

On the first day of each study, one mouse in Group 1 was treated with Trypsinogen/Chymotrypsinogen A at the lowest dose (0.254/1.521 mg/kg for Study #1). As there were no prolonged severe adverse effects within two hours of treatment, the remaining three mice in each of these groups were similarly treated.

As there were no prolonged severe adverse effects within 24 hours of initial treatment in Group 1 mice, one mouse in Group 2 was treated with Trypsinogen/Chymotrypsinogen A at 0.381/2.282 mg/kg for Study #1. As there were no visible signs of toxicity within two hours of this treatment, the remaining mice in each of these groups received the same treatment.

WO 2017/079802

PCT/AU2016/051082

Treatment continued in this manner for the remaining two doses of

Trypsinogen/Chymotrypsinogen A for Study #1 (0.572/3.423 and 0.858/5.135 mg/kg) to animals in Groups 3 and 4, respectively.

All animals in each group in each study received seven consecutive daily treatments.

Mortality	Mortality checks were performed once daily in the morning during the study.
Clinical Observations	Animals were checked for clinical signs (such as ill health and behavioural changes) twice daily during the study.

Body Weights Body weights were recorded for all animals on the first treatment day, then daily during the treatment period and for seven days following final treatment.

Clinical Observations:

From Distance

Gait	Normal or Abnormal
Piloerection	Normal or Abnormal
Type of breathing On Handling	Normal or Abnormal
Inquisitive & alert	Normal or Abnormal
Body temperature	Normal or Abnormal
Skin Tone	Normal or Abnormal
Eye condition (pale, sunken)	Normal or Abnormal
Dehydration	Normal or Abnormal
Diarrhoea	Normal or Abnormal
Abdomen (distended/swollen)	Normal or Abnormal
Other signs of adverse reaction to drug or ill health	Normal or Abnormal
Signs previously observed, e.g. in a previous study or with other species	Normal or Abnormal
Skin Reddening/lmtation e.g. Radiotherapy side	Normal or Abnormal

WO 2017/079802

PCT/AU2016/051082 effects

Body condition

BC1, BC2, BC3, BC4, BC5

Assessment Criteria for Clinical Observations:

Gait: Limping, Paresis, Paralysis = Abnormal

Body Temperature: Warm or cold = Abnormal

Type of breathing: Rapid; Shallow or Laboured = Abnormal

Diarrhoea: Loose faeces on floor of the cage, pools of faeces on floor of the cage or running out on handling = Abnormal

Body Condition (Ref: Ullman-Cullere & Foltz. Lab. Animal Science 1999; 49:319): BC1 = Animal is emaciated; BC2 = Animal is underconditioned; BC3 = Animal is wellconditioned; BC4 = Animal is over-conditioned; BC5 = Animal is obese

Clinical Observations and Adverse Events for Study #1

No adverse clinical signs were observed in any animals during the study.

Body Weight Changes

There was mean body weight gain over the course of the study (Study Days 0 to

13) for each group (2.59%, 7.48%, 7.97% and 2.03% of initial weight for animals treated with Trypsinogen and Chymotrypsinogen A at 0.254/1.521, 0.381/2.282, 0.572/3.423 and 0.858/5.135 mg/kg; Groups 1,2, 3 and 4, respectively) (Table 2 and Figure 1). No animals lost body weight in excess of 15% of initial weight (Table 3).

Example 2

Surprisingly, the amounts of Trypsinogen and Chymotrypsinogen A in Study #1 were well tolerated as shown from the results in Example 2 above. This was unexpected given these amounts were significantly above amounts previously used. In view of these results, a further study, Study #2, was performed using amounts of

WO 2017/079802

PCT/AU2016/051082

Trypsinogen and Chymotrypsinogen A, in combination, at even higher than ever previously used amounts.

For Study #2, a stock solutions of Trypsinogen and Chymotrypsinogen A were prepared at 5 and 6 mg/mL respectively. The stocks solutions were further diluted in PBS to prepare the dosing solutions of Trypsinogen/Chymotrypsinogen A for Group 1 of 0.256/1.5 mg/ml. For Groups 2 and 3, a stock solutions of Trypsinogen and Chymotrypsinogen A were prepared at 30 and 100 mg/mL respectively.

The stocks solutions were further diluted in PBS to prepare the dosing solutions of Trypsinogen/Chymotrypsinogen A for Group 2 of 8.68/50 mg/ml and for Group 3 of 4.34/25 mg/ml. It was noted that at a concentration of 50 mg/ml Chymotrypsinogen A was almost at the limit of viscosity for tail vein injection.

For Study #2 12 mice were randomised by body weight into three groups of four mice. The dosing regimen used for the study is summarised in Table 4. Trypsinogen and Chymotrypsinogen A were administered in combination as a single intravenous tail vein injection (i.v.) at doses of 10 mL/Kg. The final concentration of Trypsinogen and Chymotrypsinogen for each group were 2.6/15, 86.8/500 and 43.4/250 mg/kg (Groups

1,2 and 3, respectively)

Treatment for each group in Study #2 was initiated in a staggered manner, beginning with the lowest dose of Trypsinogen/Chymotrypsinogen A, and then increasing the dose on each subsequent study day. For all data calculations and presentation, the first day of treatment for each group is designated as Study Day 0.

On the first day of each study, one mouse in Group 1 was treated with Trypsinogen/Chymotrypsinogen A at the lowest dose 2.6/15 mg/kg. As there were no prolonged severe adverse effects within two hours of treatment, the remaining three mice in this group were similarly treated.

As there were no prolonged severe adverse effects within 24 hours of initial treatment in Group 1 mice, one mouse in Group 2 was treated with Trypsinogen/Chymotrypsinogen A at 86.8/500 mg/kg for Study #2. As there were no visible signs of toxicity within two hours of this treatment, the remaining mice in each of these groups received the same treatment.

WO 2017/079802

PCT/AU2016/051082

Treatment continued in this manner for the remaining dose of Trypsinogen/Chymotrypsinogen A for Study #2 (43.4/250 mg/kg) to animals in Group 3.

Clinical Observations and Adverse Events for Study #2

There were no adverse clinical signs observed in animals treated with

Trypsinogen and Chymotrypsinogen A at 2.6/15, and 43.4/250 mg/kg; Groups 1 and 3, respectively) (Table 5).

Reddening of the skin on the tail and temporary minor clot formations in the tail vein at the injection site were the only adverse signs observed, occurring immediately following dosing in the highest dose group (Trypsinogen/Chymotrypsinogen A at

86.8/500 mg/kg) and resolved by the time of the next dose administration (Table 5). The clinical signs did not interfere with proper dose administration.

Body Weight Changes

There was mean body weight gain over the course of the study (Study Days 0 to 13) for each group (6.98%, 4.30% and 6.61 % of initial weight for animals treated with

Trypsinogen and Chymotrypsinogen A at 2.6/15, 86.8/500 and 43.4/250 mg/kg; Groups

1,2 and 3, respectively) (Table 6 and Figure 2). No animals lost body weight in excess of 15% of initial weight (Table 7).

Table 1: Dosing Regimen for Study #1

	Test Article	Tceatsseat Tcesteeto Sdted&te
		§.254/1.521 .to IS ssL^g ₇ as a ssssfe i.v. Hqectssn ' ~

Clij’ai-atiyysiasgea A ssg&g is. naLTg as a stogie Lv. tojscttos daily fto 7

0.572/3.42 sagtog to W as s. sssigte i.v. issjectscs

T3yy>stosggto O.W5..135 isg&g la 10 ssL»lg

A as a stogie i.«. isjecttoa

OBce daily fci 7 days

Tteatoseto vs ssifetoed to each to » staggered jaaaseg begtostog with &s .to^est jfese aad toes tocieastog he dsse c-a estih suhsequest day. Fsr all data cgktoatkw sad psesestotisa, toe fet day teesrisest for eads gossip is designated. as Study Day 0.

WO 2017/079802

PCT/AU2016/051082

Table 2: Mean Body Weight Measurements ± SEM (g) for Each Treatment Group at Initiation and Termination of Study #1

Grottp	Tseatsneii'	B®dy Wesgist Bedy Weight Stedy Say 0 Fisial Day (sseas + $ΪΜ5 (mess ± SEM}	Defts Body S&nivai Weight {%) Nsmber
I	TsypsissssEi' Chvssotrypsfo&g®	Ώ A	1§.S6±S3S 28.3giS..43	3.59 «
—	$ .3.541.521 sigil Trypsins se4	kg	—	—
	Chysishy^smsgg osiawwi ·£>	21A kg	3OS±a3& 21.56 ±&30	7.48 4'4
3	Trypsissgsib·	21A	207 + 8.11 21.W + 851	7. §7 4'4
	$572/3.423 sigil	kg
4	Tiypriseges/ Cfiymstsypsisege	21A	21.18 + 8.48' 2Ldl + 8J1	3.S3 44
	058,5.135 sigil	kg
Treafoseifo »	®ie administered as &	isgte i.v.	sidecdfiss, saee <My for seven.;: aaserrU	eve days.

Iteataaad was: mfisted t® each group ia a staggered massier, begssfoag Λ the fowest dfcse and thesi iacreasisg die ctese sss each subseqsssst dsy. For sd d.a?·. csicidafisss sad preseafossss, ihs first day af teataesr far each giiKsp is designated as Stady Day 0.

Table 3: Initial Body Weight and Occurrence of Lowest Body Weight (g) for

Each Animal During the Course of Study #1

WO 2017/079802

PCT/AU2016/051082

Grasp	Treatment	Asimat ID	Shards g Weigfit (g)	Lswest Weight	Days .Fsst Isdfial Tseaiment	Beta Start to Lcwest (W
		S7343	28.7$	19.53	5	-5.7
	Tfe^saLogss/Chwcfepsimsgen. A	11414	19.17	19.78	12	-8.9
	8.254/1.52 ί mg/kg.	37SSG	20.01	19.«	11	-1.7
		43δ2δ	107	107	0	0.0
		8731$	19.7$	19.1S2	4	-8.4
7	TtypsiMgmOyin&hyptissges A	15dd3	19.&B	19.71	2	-8..9
	8.381/2.282 mg/kg	25443	20.95	28.95	0	00
		45040	19.71	19.65	2	-03
		14447	20.48	28.48	$	8.8
	TiypsBsgesyCfems&byjsissgeH A	17672	20.40	20.49	0	00
.?	0.572/3.423 mg/kg	25190	20.«	28.46	s	00
		45377	20.05	28.85	0	8.8
		8S3S4	21.25	21.25	8	00
4	Tiy'psiaG.ges/C.hj'sistjy'pisiss ges. A	2om	21.02	2L52	1	-1.4
	0.§5S/5.l35rsgAg	2S0S0	20.02	19.19	2	-4.1
		311S7	21.63	28.88	2	-3J

Treaimefes were sdssimstered as sfegfe Lv. fojecticB, ®®ce daily for sevesxs^ecsfcs days.

Trefemsfe wax mfested to each grsup is a staggered masuer, begssfesg. with toe fewest dose asfe thesj iscreasisg fee das« es. each subsespefe day. Fw all. dfea £&ksixfems sad psesentaifoa, the fest day s?f teestmefe fez each gisxsp is designated xs Sfesdy Day 0..

Table 4 : Dosing Regimen for Study #2

-Grssp Test Arfele Treatment Ikeajfesefe Sehedsle
I	Trypsfeesefe C'feTnsfejpsfesges A	2.6/15 mgfeg fe 1$ mL/kg as a. single iA·. fejecfem	Cfoce daily for 7 days
'2	liypsmQgefe Chyassfryjoasgeu A	M>5W mg/kg in 10 mLAg as a. SAiSle i.v. fejee fem	Once dslfe for 7 days
3	Trypsmcigest Chymctoypssssgeia A	43.4/258 mg/kg in l&isLAg as a sfegfe is. injecifon.	Once daily for 7 days

Treatmefe was- mitafedte each gs®np m a staggered manner.. begimfeag wife the fewest ds.se sb fee first day u fees isereatisf the dsse to 'SypfeffisgmOymstTypssssges A at &O/5W sigfeg <si the se&cmd day TsefeseE with ThypsfesgefeChysssttypsfeagea A at 43.4/258 mg/kg ismmsaced sn the third dsy. Far all dsfe calmhfess: sad peaeEtalisE, fee fei day ef tseaisaesd fbiesah gxo^t A dessgsated as Stssdy Day 8·.

WO 2017/079802

PCT/AU2016/051082

Table 5: Clinical Observations and Adverse Events for Study #2

Afejsst ,H>	Ohssrvs&iss. TyjS*	Bessrfe&si	Study Days ©feaes-vied	E.stl^ t.«riais,atfes.
3744333 3724S22 373S3S5	-	-	-	-
373S4SS

&·®ΐφ 2.: A si SS..®.^:*46s rng.ikg

Amasssl IS	Ofe’Ess^’sifess Tyjse·	Deser^the	Study Dssys Ofees'sed	Easly i«Fi££KSSa&tS;
3745774	.3£sd ]?·ξ£ί	SklEL on Tsdi	2 to 4
Cissttiag ap^sssisg ’ss dsiisd tail vein	-	3
3717536	Skfe asfe Fms	SLeddeaeh Sfe sas Tsd	Lfe
Ck-fess sppssfetg: fe fessfi. tail vke	-	3 »4
3737Sfe	Skl3S 3SS& ^ 551'	Kedfefe Skis sss Tad	i 50 5
tw dos-ed s-sd v-em	-	3
373356©	Skus .32sd FfU:'	Skis on Txsi	Ito 5
Ckfessg ap-psasfeg ia hated tail veas.	-	3

Givjvip 3:; A 43.4·liSiaj.kg

Afessdi S> O&s«rvsti«B. Type- Desei^rts.oii.

:Siudy Days Early Observed teraaissatfess.

3714W

3716814

3734445

3746S01

Tssstaefe *K fetfifeed ts each gs®ip fe a staggered mssser, begfefeg with fee fewest tfese ®a fee ferst fey slid fliesi fecisssisg fee fee ta TsypdnegfeChyiiiefe^fetsgen. A. at Sd S.ASS mg/kg sis file sewsd day. Ifefesefe ws.fe fepfe«ffeCh}?ia®tn^5fegesi A at 43.4/258 sighg «Gssmescedi sa the fifed day. For ah fea caksiatkjas ss.d ^sefestfen, &e fast -day ©f teesimest for each grssp is designated as Sfedy Day 8.

Table 6: Mean Body Weight Measurements ± SEM (g) for Each Treatment

Group at Initiation and Termination of Study #2

WO 2017/079802

PCT/AU2016/051082

Grssp	Treataejit	Bedy Weight Sfedy Bay S {saessa. ± SEM)	Sfeiy Weight .Eisai Dav (aaesii ± SEA·!)	Delia Bedy Ssrvh'al Weight (%) NeBiber
1	Tnyftwgefe Chymsfryp-tiEstgen A 2. S215 ssgfeg	31.29 ±OSS	22.77 ± 07	08 4M
:2	Tn'psfeegefe Chymrtteypfensgffii A SO/5W sigdig	21.23 ±L4S	22.. 14 i 1.52	4 20	4M
3	Trypfessgen/ Cfeysn®fiypsi»s§s3. A	2OG±Llg	22.07 =:0 95	O1	4M

43.4./250ss£ikg

Ttesfinefes were afetfetistered ss single Lv. iajestisss, ©see daily foi seven e®a$eefeive days.

Trestasefe s^:ss isifefeed is each is a staggered ssanser, bsgfesssg wife fee bsmt dsse sb fee tot day sad fees fecieasfeg ihe cose is Ttypwsgesj'Chj'aiotiypsissgffi A st M8/5W ciglg sn fee aecssd day TresUisesi wife Trypahege^C^yEBis&ypsfesg^. A st 43.4/25 0 mg/kg ©oimsessed ss the third day. Far all data esfcfesfeas· sad presentation, the first day ®f trestmsfe for esch grsnp is designated as Stedy Day 6.

Table 7: Initial Body Weight and Occurrence of Lowest Body Weight (g) for Each Animal During the Course of Study #2

Gsnnp IrestHseat	Afesitfe ID	Sisrifeg Weight €)	Lowest Weight ig/	Days ?<>:;. Initial Ites.tsaeHi	Delia Start is Lowest mi
	04333	28A9	30.21	1	-3..3
_λ TrypssB©§ra/ChyEBohypm^«s A	24S2.2	23.82	2319	2	-2.6
2.6/15 mgilg	30389	14.64	19.46		-1.2
	37400	20.79	20.50	2	-1.4
	S5774	18.85	18.73	I	-0.6
Tsy]3sfe&g£siiOyHstEyp.ssEag€S3. A	17536	20.76	20.35	2	2 0
SO/Wmg^g	27819	25.59	24.83	2 and 7	-2.6
	335W	19.81	19.57	6	-1.2
	14640	19.38	19.38	6	0:.0
. Tsypsbog^/Chy’asshypsiEsgm A	167:4	20.98	208	0	0.0
’ 416/250 mgd;g	34449	19.15	19.15	0	0:.0
	46891	24.20	24.18	5	-0.1

Trestsssenis were sdanfeslered as Single i.v, iryedim, ease daily fear se ven sisssesssisye days.

Treatasefe wss infested b each, .groap is a staggered manner, begfessng wife the fewest fesse on the last dry ®ssd fees fene&sisg fee dose is Trypsssege®.O.ymeh^ss.^es A at 86.8/560 sngfeg sn fee se&sad day Treafessd wife Ts^psbcgEa/ChyimirypaisKsges A at 43 42250 mgfeg cssEsraensed ©a fee fifed day. Far sfi fetfe cakndfesisas sad pteseniaik®, fee fet day of treafeasfe &c ss.ch gronp is designated ss Sfesdy Day 0.

WO 2017/079802

PCT/AU2016/051082

Example 3

The study was performed to assess anti-tumour efficacy of Trypsinogen and Chymotrypsinogen A, administered in combination against Pan02 mouse pancreatic cancer cells, orthotopically inoculated in female C57BL/6 mice.

Cell Line

Pan02 mouse pancreatic tumour cells were sourced from National Cancer Institute (Frederick, MD, USA).

Tumour Cell Culture

Pan02 mouse pancreatic tumour cells (working stock VP-Stock 1235) were cultured in RPMI 1640 cell culture medium supplemented with 10% FBS, 1% GlutaMAX™ and 1% penicillin-streptomycin, and grown at 37°C in a humidified cell culture incubator supplied with 5% CO2. The cells were harvested (Passage 7) by trypsinisation, washed twice in HBSS and counted (using trypan blue exclusion). The final cell density was adjusted with HBSS:Matrigel^TM (1:1, v/v) to 5 χ 10⁷Pan02 cells/mL.

The use of Mathgel™ in the inoculation suspension is known to support early vasculahsation which can increase the take-rate of tumours, and therefore has the potential to decrease tumour size variability.

Tumour Cell Inoculation

Forty C57BL/6 female mice were inoculated while under intraperitoneally injected anaesthesia (Ketamine (14 mg/mL)/Xylazine (0.9 mg/mL)). Prior to inoculation, the skin at the incision site was swabbed with topical povidone iodine solution and then alcohol. An incision was made to expose the pancreas. A needle was introduced directly into the pancreas tail where 20 pL of cell suspension, consisting of 1 χ 10⁶ Pan02 cells, was discharged.

Mice were administered a 200 pL bolus dose of Buprenex (Buprenorphine HCI, 0.01 mg/mL) subcutaneously for pain relief at the time of surgery and the following day.

WO 2017/079802

PCT/AU2016/051082

Tumour Take-Rate Determination

Ten randomly selected animals (Group 0) were euthanised seven days post inoculation to assess the size and take rate of tumours in the pancreas. The pancreas was excised and examined for the presence of a tumour.

The presence of a tumour was confirmed in the pancreas of all 10 of these animals.

Randomisation

Two days following confirmation of successful tumour take-rate, 30 of the remaining animals were randomised, based on body weight, into three groups of 10 (nine days post-inoculation; Study Day 0).

Compound Formulation

Trypsinogen and Chymotrypsinogen A were dissolved in phosphate buffered saline (PBS) on each treatment day to give stock solutions of 1 mg/mL. The dosing solutions of Trypsinogen/Chymotrypsinogen A at 2.75/16.5 and 8.33/50 mg/mL (ratio of 1:6) were prepared by diluting the Trypsinogen solution first in PBS and then adding Chymotrypsinogen A.

Compound Administration

The dosing regimen used in this study is summarised in Table 8.

The animals assigned for take-rate assessment (Group 0) remained untreated.

Vehicle Control (PBS; Groups 1) and Trypsinogen/Chymotrypsinogen A (in combination in a single injection) at doses of 27.5/165 (Group 2) and 83.3/500 mg/kg (Groups 3) were administered once daily i.v. in a dosing volume of 10 mL/kg. The volume of dosing solution administered to each animal was calculated and adjusted based on individual body weight measured immediately prior to dosing.

Treatments commenced on Study Day 0 (nine-days post-inoculation). Treatments were administered to animals in Groups 1,2 and 3 for 26 consecutive days.

WO 2017/079802

PCT/AU2016/051082

Termination Procedure

All take-rate assessment animals and those in Groups 1, 2 and 3 were euthanised via carbon dioxide inhalation by approved standard procedures.

Sample Collection

Upon termination, the pancreas was excised from all animals with tumour intact. The tumour was isolated from the pancreas tissue, weighed and then photographed (Figures 4 to 6). A 25 mg portion of tumour from each of the samples in Groups 4 and 5 were stored at -80°C and shipped to Adaptive Biotechnologies Corp, for further analysis.

Calculations

Mean percentage change in body weight (%BW Change) between Day 0 and any given day (Day X) was calculated using the equation:

%BW Change = mean(BWstudyDayx)/mean(BW_StudyDay o) ^x 100% -100% where BWstudy Day o = initial value on Day 0 and BWstudy Dayx = current value on Day X.

Percentage change in mean tumour weight for treated groups relative to the control group was calculated using the following equation:

Percentage change = ((Mean_Controi - MeanTr_eatment)/Mean control) ^χ100

Statistical Calculations

All statistical calculations were performed using Prism 6 for Mac OS X (GraphPad Software Inc, La Jolla, CA, USA).

Normality of all data-sets was tested using the Kolmogorov-Smirnov (KS) normality test.

A paired t-test was used to determine if body weight changed significantly within a treatment group between Study Day 0 and the termination day of each group.

Comparison of tumour weight at termination of the study was made between

Groups 1,2 and 3 using One-Way Analysis of Variance (ANOVA). Significant

WO 2017/079802

PCT/AU2016/051082 differences between groups were determined using Holm-Sidak’s Multiple Comparisons Test.

A p value of < 0.05 was considered significant.

Results and Observations

Body Weight Changes

There was a small (not significant) mean body weight loss (0.54% of initial weight) in animals treated with Vehicle Control for 26 days (PBS; Group 1).

All other groups showed mean body weight gain; 0.82% and 2.72% of initial weight for groups treated with Trypsinogen/Chymotrypsinogen A at 27.5/165 and 83.3/500 mg/kg for 26 days (Groups 2 and 3, respectively).

Efficacy of Compounds

There was significant (p<0.05) reduction in mean tumour weight in animals treated for 26 days with Trypsinogen/Chymotrypsinogen A at 83.3/500 mg/kg (30.2 mg; 85.9% inhibition; Group 3) compared with Vehicle Control (PBS; 214.8 mg; Group 1), but not between Trypsinogen/Chymotrypsinogen A at 27.5/165 mg/kg (196.5 mg; 8.5 % inhibition; Group 2) and the Vehicle Control (Table 9 and Figure 3).

Conclusion

Anti-tumour efficacy of daily treatment with Trypsinogen and Chymotrypsinogen A, administered in combination as a single intravenous injection at doses of 27.5/165 or 83.3/500 mg/kg, was assessed against Pan02 mouse pancreatic cancer cells, orthotopically inoculated in female C57BL/6 mice.

Measurements of tumour weight at termination showed significant (p<0.05) antitumour efficacy in animals treated with high-dose Trypsinogen/Chymotrypsinogen A compared with control-treated animals after 26 days of treatment in this study.

Table 8: Dosing Regimen

Group

Number of

Test Article

Treatment

Treatment Schedule

WO 2017/079802

PCT/AU2016/051082

Animals
0	10	No treatment (for take-rate assessment)	-	-
1	10	Vehicle Control (PBS)	10 mL/kg, i.v.	Once daily (Study Days 0 to 25)
2	10	Trypsinogen/ Chymotrypsinogen A	27.5/165 mg/kg in 10 mL/kg as a single i.v. injection	Once daily (Study Days 0 to 25)
3	10	Trypsinogen/ Chymotrypsinogen A	83.3/500 mg/kg in 10 mL/kg as a single i.v. injection	Once daily (Study Days 0 to 25)

Table 9: Mean Tumour Weight ± SEM at Termination (mg) for Each Group

Group	Treatment	Teraiinariou Day	Namber of Ammajk	Mean Tvseor Weight ± SEM (me)	% Tiimsw iahibiiion*
1	Vehicle Contol (PSS)	26	8	214.8 ±23.4	N/A
2	Trypsinogen/ Chymoteypsinogea A 27.5/165 mg/kg	26	9	196..5 ±30.5	8 5
3	Trypsinogen/ ChTOiotH.'pamogea A 83..3.S00 mg/kg	26	10	30.2 + 8.2^	85.9

Treatments were administered as a single i.v. injection, once daily (Study Days 0 5 to 25 for Groups 1,2 and 3. Groups 1, 2 and 3 were terminated on Study Day 26.

Tumours were not collected from animals that were found dead (one each in Groups 1 and 2). The value for one animal in Group 1 that was euthanised on Study Day 6 was not included in the analyses.

^a p<.05 compared with Group 1 (p<0.05; Holm-Sidak’s Multiple Comparisons 10 Test).

^b p<0.05 compared with Group 2 (p<0.05; Holm-Sidak’s Multiple Comparisons Test).

Mean tumour weight ± SEM for each group are depicted in Figure 3.

WO 2017/079802

PCT/AU2016/051082 * % Tumour inhibition was calculated for Groups 2 and 3 using Group 1 as the control.

N/A: not applicable

Example 4

The study was performed to assess anti-tumour efficacy of Trypsinogen and Chymotrypsinogen A, administered in combination, against A2780 human ovarian cancer cells orthotopically inoculated in female Athymic Nude-Foxnf™ mice.

Cell Line

A2780 human ovarian carcinoma cells were sourced from National Cancer Institute (Frederick, MD, USA).

Tumour Cell Culture

A2780 human ovarian cancer cells (working stock VP-Stock 1277) were cultured in DMEM supplemented with 10% FBS, 1% GlutaMAX™ and 1% penicillinstreptomycin, and grown at 37°C in a humidified cell culture incubator supplied with 5% CO2. The cells were harvested (Passage 8) by trypsinisation, washed twice in HBSS and counted (using trypan blue exclusion). The final cell density was adjusted with HBSS:Mathgel^TM (1:1, v/v) to 2.0 χ 10⁸ cells/mL.

Tumour Cell Inoculation

Sixty athymic Nude-Fox/?/™ mice were inoculated while under intraperitoneally injected anaesthesia (Ketamine (14 mg/mL)/Xylazine (0.9 mg/mL)). Prior to inoculation, the skin at the incision site was swabbed with alcohol. An incision was made to expose the ovary. A needle was introduced directly into the ovary where 5 pL of cell suspension, consisting of 1 χ 10⁶ A2780 cells was discharged.

WO 2017/079802

PCT/AU2016/051082

Mice were administered a 200 μΙ_ bolus dose of Buprenex (Buprenorphine HCI, 0.01 mg/mL) subcutaneously for pain relief at the time of surgery and the following day.

Randomisation

The animals were randomised, based on body weight, into five groups of 12 and one group of 24, 7 days post-inoculation (Study Day 0).

Compound Formulation

Trypsinogen and Chymotrypsinogen A were dissolved in phosphate buffered saline (PBS) on each treatment day to give stock solutions of 30 and 100 mg/mL, respectively. Dosing solution of Trypsinogen/Chymotrypsinogen A at 8.33/50, 2.75/16.5 and 0.91/5.4 mg/mL (ratio of 1:6) were prepared by diluting Trypsinogen solution first in PBS and then adding Chymotrypsinogen A.

Compound Administration

The dosing regimen used in this study is summarised in Table 10.

Animals in Group 1 remained untreated for tumour take-rate assessment.

Vehicle Control (PBS; Group 2) and Trypsinogen and Chymotrypsinogen A at doses of 83.3/500, 27.5/165 and 9.1/54 mg/kg (Groups 3, 4 and 5, respectively; in combination in a single injection) were administered once daily via intravenous (i.v.) tail vein injection in a dosing volume of 10 mL/kg (12 animals per group). The volume of dosing solution administered to each animal was calculated and adjusted based on individual body weight measured immediately prior to dosing. Treatments commenced on Study Day 0 and were administered for 21 consecutive days.

Tumour Take-Rate Determination

The untreated animals in Group 1 were euthanised seven days after the onset of treatment (14 days post-inoculation) to assess the size and take rate of tumours in the ovary.

WO 2017/079802

PCT/AU2016/051082

The presence of a tumour was confirmed in the ovary of all 12 animals, then the tumour was isolated from the excised ovary and weighed for all animals. Tumour photographic images are presented in Figures 8 to 11.

Termination Procedure

All animals were euthanised via carbon dioxide inhalation by approved standard procedures (Groups 1 through 5).

Sample Collection

Upon termination, the ovary was excised from all animals with tumour intact. The tumour was isolated from the ovarian tissue and weighed. Tumours from animals receiving 21 days of treatment (Groups 2 through 5) were also photographed.

Calculations

%BW Change = mean(BW_StudyDayx)/mean(BW_StudyDay o) ^x 100% -100% where BWstudy Dayo = initial value on Day 0 and BWstudy Dayx = current value on Day X.

Percentage inhibition of tumour growth for treated groups relative to the control group was calculated using the following equation:

Percentage inhibition = ((Mean_Controi - Mean_Treatment)/Mean control) ^χ100

Statistical Calculations

Normality of all data-sets was tested using the D’Agostino and Pearson omnibus normality test.

A paired t-test was used to determine if body weight changed significantly within groups receiving 21 days of treatment (Groups 2 through 5) between Study Day 0 and

WO 2017/079802

PCT/AU2016/051082 termination of the study. Where the data was not normally distributed, significance was determined using the Wilcoxon Matched Pairs Signed Rank Test.

Comparison of tumour weight at termination of the study was made between groups receiving 21 days of treatment (Groups 2 through 5) using One-Way Analysis of Variance (ANOVA).

A p value of < 0.05 was considered significant.

Results and Observations

Body Weight Changes

There was significant (p<0.05) mean body weight gain between Study Days 0 and 7 in untreated animals (4.33% of initial weight; Group 1).

There was mean body weight gain between Study Days 0 and 21 in the groups treated for 21 days with Vehicle Control (PBS; 6.56% of initial weight; Group 2) and all doses of Trypsinogen/Chymotrypsinogen A (83.3/500, 27.5/165 and 9.1/54 mg/kg; 8.60%, 6.00% and 3.89% of initial weight; Groups 3, 4 and 5, respectively). Body weight gain was significant (p<0.05) in all groups except low-dose treatment (Group 5).

Efficacy of Compounds

There was significant (p<0.05) reduction in mean tumour weight in animals treated for 21 days with mid- and low-dose Trypsinogen/Chymotrypsinogen A (27.5/165 and 9.1/54 mg/kg; 957.3 and 1074.2 mg; 53.6% and 47.9%; Groups 4 and 5, respectively) compared with Vehicle Control (PBS; 2062.2 mg; Group 2), but not highdose Trypsinogen/Chymotrypsinogen A (83.3/500 mg/kg; 1762.2 mg; 14.5%; Group 3) (Table 11 and Figure 7).

Tumour weights for untreated animals (Group 1) euthanised on Day 7 for takerate assessment were not included in the analysis.

Conclusion

Anti-tumour efficacy of daily treatment with Trypsinogen and Chymotrypsinogen A, administered in combination as a single intravenous injection at doses of 83.3/500,

WO 2017/079802

PCT/AU2016/051082

27.5/165 or 9.1/54 mg/kg, was assessed against A2780 human ovarian cancer cells, orthotopically inoculated in female athymic nude-Foxn1^nu mice.

Measurements of tumour weight at termination showed significant (p<0.05) antitumour efficacy in animals treated with mid- and low-dose Trypsinogen/

Chymotrypsinogen A compared with Vehicle control-treated animals after 21 days of treatment in this study. Significant anti-tumour efficacy was not observed following highdose treatment.

Table 10: Dosing Regimen

Granp	T&stArridie	Treataeot	Treahsest Sdsedale
I	(take-rate assessing)	-	-
2,	Vehicle Control (PSS)	10 mL/kg, i.v.	ssce dsfy (SfeKfy Days 0 to 20)
3	Trypsfooge®	S33/500 mg/kg isi IS niL'kg as s single i.v: i^eetioo	saee daily (Sfedy Days 9^: to 20}
4	TiypaaogesV Chyiwirj^wsgen A	27.5/165 sig^fkg is IS iriL/kg as a single i.v: injection	jace daily (Stedy Days S to 20}
5	TsvpsinogetV	9/54 xKg^;k§ in 10 mL/kg as a. single i.v. mjecwi	once daily (Sftsfy Days 0 to 20)
6	TtyprimgesW	S3.3/50G mg/kg m 10 nsl/kg as a single i.v. mjedios.	osce on Stssfy Day 19

Table 11: Mean Tumour Weight ± SEM at Termination (mg) for Each Group

WO 2017/079802

PCT/AU2016/051082

	Treatment	Number	Tenninatiw Day	Meas Im» Weight ± SEM	% Terneor
1	Nsteestmcasi (take-sale assessrnem)	12	7	310 ± 9.G	N/A.
2	Whicfe (P8S)	12	21	20S2..2± 331..4	N/A
.3	Uypsisogea·'' Cfesatrvp-smsgen A	12	21	1762.2 ±142.4	14..5
4	Tiypsmogea/ 27.5/Ϊ55 mgtg	1 A	21	937.3 ±232.9 «	53..0
.5	Trjpsiwgim/ Qiymotiypswjgea A 9..1,64 mg/kg	12	21	W74.2± 225..5⁸	47..9

Untreated animals in Group 1 were euthanized on Study Day 7 (14 days postinoculation) for tumour take-rate assessment. Tumour weights for animals in Group 1 were not included in the statistical analysis.

Treatments were administered to animals in Groups 2 through 5 as a single i.v. injection, once daily (Study Days 0 to 20). These animals were terminated on Study Day 21.

a: p<0.05 compared with Group 2 (Holm-Sidak’s Multiple Comparisons Test).

Mean tumour weight ± SEM for each group is depicted in Figure 7.

N/A: not applicable

Example 5

Human dose conversion can be by any of the relevant methods described in U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Estimating the Maximum Safe Starting Dose in 15 Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Rockville, MD 2005, incorporated herein by reference.

WO 2017/079802

PCT/AU2016/051082

For example, the Human Equivalent Dose from a dose that has been administered to a mouse can be determined as follows:

Human Equivalent Dose (HED in mg/kg) = Animal Dose (mg/kg) χ Animal K - Human K, where K is a correction factor reflecting the relationship between body weight and body surface area.

For a typical adult (body weight 60 kg, body surface area 1.6m²), K is 37 and mouse K is 3. For example, 500mg/kg amount described herein can be converted to about 41 mg/kg for an equivalent human dose, and other exemplary conversions using this formula include:

Chymotrypsinogen:

Mouse (mg/kg): 1.5, 2, 3.5, 5, 15, 45, 135, 250 and 500.

Human (mg/kg): 0.12, 0.16, 0.28, 0.4 , 1.2, 3.6, 11,20 and 41

Trypsinogen:

Mouse (mg/kg): 0.25, 0.4, 0.6, 0.8, 2.5, 8, 20,40 and 80.

Human (mg/kg): 0.02, 0.03,0.05,0.065, 0.2, 0.65, 1.6, 3.2 and 6.5.

Chymotrypsinogen:

Mouse (mg/kg): 15, 54 165, 250, 500.

Human (mg/kg): 1.2, 4.4, 13, 20 and 41.

Trypsinogen:

Mouse (mg/kg): 2.6, 9, 27.5, 43.4, 83.3, 86.8.

Human (mg/kg): 0.2, 0.7, 2.2, 3.5, 6.75 and 7.

The present invention includes human conversions for all amounts in mg/kg referred to herein, including Tables 1,4, 8 and 10 and anywhere else in this document, based on

WO 2017/079802

PCT/AU2016/051082 human body weights of 50, 60, 70, 80, 90, 100 or more kg and body surface area of 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8 or more m².

The human equivalent doses described herein are derived using the methods described in the CDER ‘Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers’ for dose conversion based on body surface area. It will be appreciated that any variation on the methods described in the CDER document may also be utilised for determining an appropriate human dose from the dosages administered to mice, as described herein (for example, in some circumstances it may be appropriate to dose scaling based on body weight rather than on body surface area). Moreover, the skilled person will also be familiar with methods for determining the appropriate dose for a juvenile human (i.e., non-adult human), as well as methods for determining the appropriate dose in a non-human organism, to which the methods of the present invention may be applied. The skilled person will also be familiar with methods for adjusting the appropriate dose depending on the intended method of administration (for example, intravenous, intramuscular, subcutaneous, topical, oral or other method of administration).

Example 6

The following experiments were performed to examine ratios of chymotrypsinogen to trypsinogen greater than 8:1.

Materials and Methods

Materials

Material Supplier

Dulbecco’s Modified Eagle Medium Invitrogen USA (Carlsbad, CA, USA) (DMEM), Eagle’s Minimum Essential

Medium (EMEM),Minimum Essential Medium (MEM), Roswell Park Memorial Institute (RPMI) 1640 cell culture medium, Foetal Bovine Serum (FBS), GlutaMAX™, sodium

WO 2017/079802

PCT/AU2016/051082 bicarbonate, penicillinstreptomycin (Pen/Strep) and trypsin

CellTiter-Blue® Cell Viability Assay

Trypan Blue

Promega (Madison, Wl, USA)

Sigma-Aldrich (St Louis, MO, USA)

Cell Culture

The following table (Table 12) shows the growth conditions and initial cell seeding densities in cells per well used in all ICso determination and combination 5 assays. The cells were cultured at 37°C in a humidified cell culture incubator supplied with 95% air/5% CO2.

	Tamssst Type·	Cell cttUsrn saediom	S+edt&g
786-0	Kidney	RPMI+10% FBS+1% GhitaMAX™ +1% Pen/Strep	400
Α278θ\|	Ovary	DMEM+10%FBS+l% GlutaMAX™+l% Pen/Strep	2500
ACHN	Kidney	MEM+10%FBS+l% GlntaMAX^+l % Pen/Strep	4000
BT-474	Breast	RPMI+10% FBS+1% GlutaMAX™ +1% Pen/Strep +1% NaHCOj	WOO
C8161.9	Melanoma	DMEM+10%FBS+l% GlutnMAX™+l% Pen/Strep	1500
DAOY	Brain	RPMI+10% FBS+1% GlutaMAX™ +1% Pen/Strep	1500
DU 145	Prostate	RPMI+10% FB-S+1% GhttaMAX™ +1% Pen/Strep	800
G-361	Melanoma	RPMI+10% FBS+1% GlntaMAX™ +1% Pen/Strep	3000
HCT 116	Colorectal	RPMI+10% FBS+1% GlntaMAX™ +1% Pen/Strep	1500
HCT-15	Colorectal	RPMI+10% FBS+1% GlutaMAX™ +1% Pen/Strep	1500
Hep3B2.1.-7	Liver	RPMI+10% FBS+1% GlntaMAX™ +1% Pen/Strep	1500
HL 60	Leukaemia	RPMI+10% FBS+1% GlntaMAX™ +1% Pen/Strep	50000
HT-1080	Fibrosarcoma	EMEM+10% FBS+1% GhitaMAX¹¹⁴ +1% Pen/Strep	1500
HT-29	Colorectal	RPMI+10% FBS+1% GlntaMAX™ +1% Pen/Strep	4000
HbH-7	Liver	DMEM+10% FBS+1% GlutaMAX™+l% Pen/Strep	4000
MCF-7	Breast	RPMI+10% FBS+1% GhttaMAX™ +1% Pen/Strep	5000
MDA -MB-33I	Breast	DMEM+10% FBS+1% GlutaMAX™+I% Pen/Strep	6000
MES-SA	Uterus	RPMI+10% FBS+1% GlntaMAX™ +1% Pen/Strep	5000
NCIII160	Lung	RPMI+10% FBS+1% GlutaMAX™ +1% Pen/Strep	400
NCI-H82	Lung	RPMI+10% FBS+1% GlutaMAX™ +1% Pen/Strep	25000
PC-3	Prostate	RPMI+10% FBS+1% GlntaMAX™ +1% Pen/Strep	2500
Raji	Leukaemia	RPMI+10% FBS+1% GhitaMAX™ +1% Pen/Strep	3000
SK-OV-3	Ovary	RPMI+10% FBS+1% GlutaMAX™ +1% Pen/Strep	1500
SNB-19	Brain	DMEM+10% FBS+1% GlutaMAX™+l% Pen/Strep	600
U--87 MG	Brain	MEM+10% FBS+1% GlmaMAX™+l% Pen/Strep	1500

All following cell lines were sourced from American Type Culture Collection (ATCC) (Rockville, MD, USA): 786-0, ACHN, BT-474, DAOY, DU 145, G-361, HCT 116,

WO 2017/079802

PCT/AU2016/051082

HCT-15, Hep3B2.1-7, HL-60, HT-1080, HT-29, MCF-7, MDA-MB-231, MES-SA, NCIH460, NCI-H82, PC-3, Raji, SK-OV-3, U-87 MG.

The A2780 cell line was sourced from the National Cancer Institute (NCI) (Bethesda, MD, USA).

The C8161.9 cell line was sourced from Dr. Gavin Robertson’s Laboratory (College of Medicine, Pennsylvania State University, Hershey, PA, USA)).

The HuH-7 cell line was sourced from the Japanese Collection of Research Bioresources (JCRB) Cell Bank (Osaka, Japan).

The SNB-19 cell line was sourced from the Deutsche Sammlung von

Mikroorganismen und Zellkulturen (DSMZ) (German Collection of Microorganisms and Cell Cultures) (Braunschweig, Germany).

All cell lines were utilized in assays up to passage 10.

Test Articles

Test Article 1

Identity:

Description:

Lot Number:

Storage Conditions:

Handling Precautions:

Manufacturer I Supplier:

Test Article 2

Trypsinogen

White powder

0F001644

-20°C

Standard laboratory precautions

Applichem (Darmstadt, Germany) I

Enzyme Supplies (Oxford, UK)

Identity:

Chymotrypsinogen

WO 2017/079802

PCT/AU2016/051082

Description:	White powder
Lot Number:	3J006510
Storage Conditions:	-20°C
Handling Precautions:	Standard laboratory precautions
Manufacturer / Supplier:	Applichem (Darmstadt, Germany) 1 Enzyme Supplies (Oxford, UK)

Test Article Formulation

Trypsinogen and Chymotrypsinogen were dissolved directly in the appropriate cell culture medium and immediately added to the cells.

Cell Growth Assays

For combination assays, Test Articles were added to cells 24 hours post-seeding. Test Article concentrations were tested in triplicate for each cell line. Seventy-two hours post addition of Test Articles, the CellTiter-Blue® Assay was carried out on all plates.

The concentration of Trypsinogen used in the combination assays was based on a calculated ICsofrom single Test Article experiments. The concentration of Trypsinogen for each individual cell line determined the concentration of Chymotrypsinogen at the following ratios: 1:1, 1:2, 1:4, 1:6, 1:8 and 1:10 (Trypsinogen:Chymotrypsinogen). Controls consisted of growth medium only and untreated cells plus growth medium (untreated control).

Assay controls used were growth medium control as a vehicle and growthmedium only (background) as opposed to phosphate-buffered saline control as vehicle and Triton-x 100 as positive control. Background subtraction was not performed for the determination of ICso values.

Following incubation of cells in Test Article-containing media, 10 pL of CellTiterBlue® was added to each well, then incubated with cells for up to 6 hours. Fluorescence was measured using a Spectramax Gemini XPS Fluorometer (560 nm excitation, 590

WO 2017/079802

PCT/AU2016/051082 nm emission). All data were recorded and entered into Microsoft® Excel spreadsheets for interpretation.

Calculations

Data collected from CellTiter-Blue® assays were plotted as dose response curves for ICso determination. Relative Fluorescence Units (RFU) were plotted against compound concentrations. In these plots, the X-axis (compound concentration) was represented in a logarithmic scale. ICso concentration was calculated as the half maximal (50%) inhibitory concentration (IC) for each compound via a variable slope curve-fitting algorithm using GraphPad Prism version 6.0e for Mac OSX (GraphPad Software, San Diego California, USA).

For combination studies, the coefficient of drug interaction (CDI) was calculated according to the following equation:

where TC is the growth inhibition of the combination of Trypsinogen and Chymotrypsinogen, T is the growth inhibition of the single agent Trypsinogen and C the growth inhibition of the single agent Chymotrypsinogen. CDI values below 1 indicate drug synergism, whereas values above 1 indicate an antagonistic interaction of Trypsinogen and Chymotrypsinogen.

Cell Growth Inhibition by Trypsinogen and Chymotrypsinogen in Human Cancer

The effect of Trypsinogen (T) and Chymotrypsinogen (C) alone or in combination on the growth of A2780 ovary tumour cells is shown in Figure 12. The greatest level of growth inhibition of A2780 ovary tumour cells was observed for ratios greater than 1:8 (T:C), for example 1:10 (T:C), see Table 13 (immediately below).

A2780

Replicates (RFU)

3 . Growth ,,,,,

Average SEM _T ...... CDI

Inhibition lx Trypsinogen 10871.031 10998.869 11247.885 11039.26 110.65 1.14

WO 2017/079802

PCT/AU2016/051082

lx Chymotrypsinogen	9854.075	10037.875	9934.535	9942.16	53.20	1.03
2x Chymotrypsinogen	7368.414	7412.912	8284.251	7688.53	298.14	0.80
4x Chymotrypsinogen	5161.410	4959.459	5351.289	5157.39	113.13	0.53	-
6x Chymotrypsinogen	4068.919	3861.354	4293.539	4074.60	124.79	0.42
8x Chymotrypsinogen	3145.061	2976.396	3189.652	3103.70	64.94	0.32
lOx Chymotrypsinogen	1531.170	1467.334	1503.991	1500.83	18.50	0.16
1:1	3569.706	3268.046	3522.157	3453.30	93.64	0.36	0.30
1:2	1473.600	1497.48	1592.828	1521.30	36.42	0.16	0.17
1:4	1060.256	1063.304	1112.314	1078.62	16.87	0.11	0.18
1:6	1012.297	992.679	994.430	999.80	6.27	0.10	0.21
1:8	959.808	879.302	939.566	926.23	24.18	0.10	0.26
1:10	873.868	861.811	758.019	831.23	36.77	0.09	0.48
Control (cells only)	9456.568	9771.397	9750.574	9659.51	101.65
Medium only	721.110	709.561	680.464	703.71	12.09	-

The effect of Trypsinogen and Chymotrypsinogen alone or in combination on the growth of C8161.9 melanoma cells is shown in Figure 13. The greatest level of growth inhibition of C8161.9 melanoma cells was observed for ratios greater than 1:8 (T:C), for 5 example 1:10 (T:C), see Table 14 (immediately below).

C8161.9	Replicates (RFU)	Average	SEM	Growth Inhibition	CDI
1	2	3
lx Trypsinogen	8522.324	7631.593	8520.562	8224.83	296.62	1.10
lx Chymotrypsinogen	6777.939	8093.121	7808.435	7559.83	399.49	1.01
2x Chymotrypsinogen	6077.701	6742.977	6393.707	6404.80	192.13	0.85
4x Chymotrypsinogen	6515.904	6079.726	5879.160	6158.26	187.96	0.82	-
6x Chymotrypsinogen	5416.613	5005.616	5229.323	5217.18	118.80	0.69
8x Chymotrypsinogen	7333.727	8090.684	8238.635	7887.68	280.25	1.05
lOx Chymotrypsinogen	5673.008	6755.334	6653.124	6360.49	345.00	0.85
1:1	5554.142	5775.944	6000.930	5777.01	128.98	0.77	0.70
1:2	3153.882	2757.958	3030.887	2980.91	116.99	0.40	0.42
1:4	1917.887	1922.872	2423.867	2088.21	167.84	0.28	0.31
1:6	1722.204	1741.576	1894.141	1785.97	54.37	0.24	0.31
1:8	1611.822	1638.031	1620.716	1623.52	7.69	0.22	0.19
1:10	1321.071	1166.744	1424.934	1304.25	75.01	0.17	0.19
Control (cells only) Medium only	7676.335 701.358	7617.46 680.206	7233.554 678.760	7509.12 686.77	138.83 7.30	-

WO 2017/079802

PCT/AU2016/051082

The effect of Trypsinogen and Chymotrypsinogen alone or in combination on the growth of DAOY brain tumour cells shown in Figure 14. The greatest level of growth inhibition of DAOY brain tumour cells was observed for ratios greater than 1:8 (T:C), for example 1:10 (T:C), see Table 15 (immediately below).

DAOY	Replicates (RFU)	Average	SEM	Growth Inhibition	CDI
1	2	3
lx Trypsinogen	9051.549	9141.617	8347.920	8847.03	250.91	1.09
lx Chymotrypsinogen	8285.778	8192.939	8384.539	8287.75	55.32	1.02
2x Chymotrypsinogen	7865.063	7416.132	7612.021	7631.07	129.94	0.94
4x Chymotrypsinogen	5604.916	5300.233	5226.702	5377.28	115.78	0.66	-
6x Chymotrypsinogen	4077.504	3677.683	3736.964	3830.72	124.57	0.47
8x Chymotrypsinogen	2896.918	2564.253	2455.450	2638.87	132.79	0.33
lOx Chymotrypsinogen	1487.412	2023.845	2125.137	1878.80	197.87	0.23
1:1	7861.021	7507.552	7543.847	7637.47	112.26	0.94	0.84
1:2	3425.338	3528.294	4562.312	3838.65	363.05	0.47	0.46
1:4	1142.231	1203.894	1154.619	1166.91	18.83	0.14	0.20
1:6	931.248	919.907	885.739	912.30	13.68	0.11	0.22
1:8	836.923	876.032	850.750	854.57	11.45	0.11	0.30
1:10	853.177	835.564	833.322	840.69	6.28	0.10	0.41
Control (cells only) Medium only	7932.601 771.175	8226.676 766.154	8164.348 457.132	8107.88 664.82	89.46 103.85

The effect of Trypsinogen and Chymotrypsinogen alone or in combination on the growth of DU 145 prostate tumour cells shown in Figure 15. The greatest level of growth inhibition of DU145 prostate tumour cells was observed for ratios greater than 1:8 (T:C), for example 1:10 (T:C), see Table 16 (immediately below).

DU145

Replicates (RFU)

3 . Growth ,...,

Average SEM _T ...... CDI

Inhibition

lx Trypsinogen	12316.109	12798.373	11894.605	12336.36	261.09	1.04
lx Chymotrypsinogen	9641.914	9745.273	9408.376	9598.52	99.64	0.81
2x Chymotrypsinogen	6119.162	6511.184	6872.414	6500.92	217.51	0.55
4x Chymotrypsinogen	4067.276	4021.511	3791.056	3959.95	85.47	0.33	-
6x Chymotrypsinogen	6162.657	6462.893	3916.473	5514.01	803.46	0.46
8x Chymotrypsinogen	6200.357	6068.926	6238.773	6169.35	51.42	0.52
lOx Chymotrypsinogen	5037.879	4455.197	4268.117	4587.06	231.79	0.39
1:1	8125.897	6246.690	8858.232	7743.61	777.74	0.65	0.78
1:2	3680.328	3374.181	3633.843	3562.78	95.25	0.30	0.53

WO 2017/079802

PCT/AU2016/051082

1:4	2269.460	2366.647	2364.699	2333.60	32.08	0.20	0.57
1:6	1943.051	2036.505	1959.739	1979.77	28.78	0.17	0.35
1:8	1838.590	1705.612	1888.048	1810.75	54.47	0.15	0.28
1:10	1786.460	1756.369	1675.614	1739.48	33.09	0.15	0.36
Control (cells only)	12466.964	12147.758	10992.462	11869.06	447.88
Medium only	893.398	833.691	828.200	851.76	20.88	-

The effect of Trypsinogen and Chymotrypsinogen alone or in combination on the growth of HCT 116 colorectal tumour cells shown in Figure 16. The greatest level of growth inhibition of HCT 116 colorectal tumour cells was observed for ratios greater than 1:8 (T:C), for example 1:10 (T:C), see Table 17 (immediately below).

HCT 116

Replicates (RFU)

3 . Growth

Average SEM _T ...... CDI

Inhibition

lx Trypsinogen	14859.604	15104.608	16112.500	15358.90	383.38	1.25
lx Chymotrypsinogen	12051.548	12853.539	13225.642	12710.24	346.42	1.04
2x Chymotrypsinogen	15683.443	16403.678	16092.573	16059.90	208.55	1.31
4x Chymotrypsinogen	11913.774	12127.43	11827.383	11956.20	89.18	0.97	-
6x Chymotrypsinogen	8377.944	8716.581	9240.221	8778.25	250.82	0.71
8x Chymotrypsinogen	6522.517	6712.549	6865.853	6700.31	99.30	0.55
lOx Chymotrypsinogen	4346.238	4803.888	4534.618	4561.58	132.80	0.37
1:1	12396.237	12051.078	11672.182	12039.83	209.09	0.98	0.76
1:2	10120.919	10732.156	10003.201	10285.43	225.94	0.84	0.51
1:4	6582.828	6926.802	6857.768	6789.13	105.06	0.55	0.45
1:6	4158.295	3803.743	3997.355	3986.46	102.50	0.32	0.36
1:8	1306.618	1395.309	1404.950	1368.96	31.29	0.11	0.16
1:10	1173.282	1172.682	1199.737	1181.90	8.92	0.10	0.21
Control (cells only)	11788.172	12334.407	12717.700	12280.09	269.70
Medium only	853.945	862.254	852.246	856.15	3.09	-

The effect of Trypsinogen and Chymotrypsinogen alone or in combination on the growth of Hep3B2.1-7 liver tumour cells shown in Figure 17. The greatest level of growth inhibition of Hep3B2.1-7 liver tumour cells was observed for ratios greater than 10 1:8 (T:C), for example 1:10 (T:C), see Table 18 (immediately below).

Hep3B2.1-7	Replicates (RFU) Growth ----------------------------- Average SEM _T . CDI 12 3 Inhibition
lx Trypsinogen	5763.579 5761.003 5278.852 5601.14 161.15 1.34

WO 2017/079802

PCT/AU2016/051082

lx Chymotrypsinogen	3690.053	3975.591	3801.437	3822.36	83.09	0.92
2x Chymotrypsinogen	3829.325	3508.687	3595.125	3644.38	95.78	0.87
4x Chymotrypsinogen	3349.295	3516.303	3482.731	3449.44	51.00	0.83	-
6x Chymotrypsinogen	3271.956	3098.025	3087.413	3152.46	59.82	0.75
8x Chymotrypsinogen	2348.604	2595.240	2850.457	2598.10	144.88	0.62
lOx Chymotrypsinogen	2513.241	2617.293	2788.512	2639.68	80.25	0.63
1:1	3980.236	4263.435	3773.279	4005.65	142.07	0.96	0.78
1:2	3308.778	2702.337	3030.569	3013.89	175.26	0.72	0.62
1:4	1182.575	1158.461	1209.168	1183.40	14.64	0.28	0.26
1:6	937.534	893.343	919.586	916.82	12.83	0.22	0.22
1:8	863.658	868.435	894.195	875.43	9.48	0.21	0.25
1:10	862.721	844.240	857.605	854.86	5.51	0.20	0.24
Control (cells only)	4078.486	4214.781	4236.280	4176.52	49.41
Medium only	695.284	697.555	695.303	696.05	0.75	-

The effect of Trypsinogen and Chymotrypsinogen alone or in combination on the growth of HT-29 colorectal tumour cells shown in Figure 18. The greatest level of growth inhibition of HT-29 colorectal tumour cells was observed for ratios greater than

1:8 (T:C), for example 1:10 (T:C), see Table 19 (immediately below).

HT-29 lx Trypsinogen lx Chymotrypsinogen 2x Chymotrypsinogen 4x Chymotrypsinogen 6x Chymotrypsinogen 8x Chymotrypsinogen lOx Chymotrypsinogen 1:1 1:2 1:4 1:6 1:8

1:10

Control (cells only)

Medium only

Replicates (RFU)	Average	SEM	Growth Inhibition	CDI
1	2	3
8223.840	8376.067	8518.233	8372.71	85.00	0.86
4538.796	4481.600	4338.855	4453.08	59.45	0.46
13525.958	14096.041	13637.257	13753.09	174.46	1.42
10580.120	10971.600	10771.067	10774.26	113.02	1.11	-
8547.735	7930.625	8223.705	8234.02	178.22	0.85
5538.742	6045.101	5833.865	5805.90	146.84	0.60
4538.783	4299.262	4388.604	4408.88	69.88	0.45
9352.964	9423.387	9389.121	9388.49	20.33	0.97	2.44
7848.395	7681.472	8119.716	7883.19	127.70	0.81	0.66
5051.926	5072.896	5130.757	5085.19	23.57	0.52	0.55
3426.633	3235.928	3040.573	3234.38	111.45	0.33	0.46
3505.802	3421.350	3548.355	3491.84	37.32	0.36	0.70
3010.496	3166.377	3032.058	3069.64	48.77	0.32	0.81
8815.367	9695.704	10592.513	9701.19	513.03
812.770	807.322	813.374	811.16	1.92	-

WO 2017/079802

PCT/AU2016/051082

The effect of Trypsinogen and Chymotrypsinogen alone or in combination on the growth of HuH-7 liver tumour cells shown in Figure 19. The greatest level of growth inhibition of HuH-7 liver tumour cells was observed for ratios greater than 1:8 (T:C), for example 1:10 (T:C), see Table 20 (immediately below).

HuH-7

Replicates (RFU)

3 . Growth ,....

Average SEM _T ...... CDI

Inhibition

lx Trypsinogen	11847.077	11647.785	11902.568	11799.14	77.36	1.14
lx Chymotrypsinogen	9654.204	9996.031	10270.954	9973.73	178.39	0.97
2x Chymotrypsinogen	8675.452	8331.810	9428.336	8811.87	323.80	0.85
4x Chymotrypsinogen	7352.330	6400.635	7106.839	6953.27	285.26	0.67	-
6x Chymotrypsinogen	6385.941	6303.662	6554.035	6414.55	73.68	0.62
8x Chymotrypsinogen	7693.982	7100.407	7891.567	7561.99	237.73	0.73
lOx Chymotrypsinogen	3056.197	3186.256	3368.272	3203.58	90.50	0.31
1:1	3151.837	2987.080	3515.283	3218.07	156.03	0.31	0.28
1:2	1513.124	1461.279	1502.350	1492.25	15.80	0.14	0.15
1:4	1020.535	1034.911	1061.719	1039.06	12.07	0.10	0.13
1:6	950.172	923.260	928.811	934.08	8.20	0.09	0.13
1:8	962.377	980.744	969.830	970.98	5.33	0.09	0.11
1:10	943.712	902.317	924.857	923.63	11.97	0.09	0.25
Control (cells only)	10366.099	10304.473	10314.27	10328.28	19.12
Medium only	783.754	745.053	749.117	759.31	12.28	-

The effect of Trypsinogen and Chymotrypsinogen alone or in combination on the growth of NCI-H460 lung tumour cells shown in Figure 20. The greatest level of growth inhibition of NCI-H460 lung tumour cells was observed for ratios greater than 1:8 (T:C), for example 1:10 (T:C), see Table 21 (immediately below).

NCI-H460

Replicates (RFU)

3 . Growth

Average SEM _T ...... CDI

Inhibition

lx Trypsinogen	12766.405	13907.190	13715.400	13463.00	352.67	1.08
lx Chymotrypsinogen	9938.641	11144.394	11179.673	10754.24	407.92	0.87
2x Chymotrypsinogen	7917.386	6785.913	7954.079	7552.46	383.42	0.61
4x Chymotrypsinogen	6269.978	6384.694	6637.457	6430.71	108.55	0.52	-
6x Chymotrypsinogen	6382.878	5722.162	6237.417	6114.15	200.44	0.49
8x Chymotrypsinogen	7626.570	8267.497	7096.047	7663.37	338.67	0.62
lOx Chymotrypsinogen	6828.383	5910.312	6399.807	6379.50	265.22	0.51
1:1	7832.132	6908.952	8165.215	7635.43	375.75	0.61	0.66
1:2	4780.923	5036.047	4030.338	4615.77	301.84	0.37	0.56

WO 2017/079802

PCT/AU2016/051082

1:4	3010.435	2684.551	2205.659	2633.55	233.71	0.21	0.38
1:6	1976.275	-	1786.417	1285.22	94.93	0.15	0.28
1:8	1589.983	1128.840	1940.589	1553.14	235.05	0.12	0.19
1:10	1021.508	1142.525	954.422	1039.49	55.04	0.08	0.15
Control (cells only)	12357.635	12437.118	12494.679	12429.81	39.73
Medium only	859.583	856.347	840.046	851.99	6.05	-

Claims

1. A method of treating cancer in a subject comprising administering chymotrypsinogen in an amount of equal to, or greater than, 3.5 mg/kg and trypsinogen in an amount of equal to, or greater than 0.6 mg/kg, thereby treating cancer.

5

2. A method according to claim 1, wherein the amount of chymotrypsinogen is equal to or greater than about 10mg/kg, 20mg/kg or 40 mg/kg, 45mg/kg, 135mg/kg, 250mg/kg or 500mg/kg;

and/or wherein the amount of trypsinogen is equal to or greater than about 1.5 mg/kg, 3 mg/kg, I0 6 mg/kg, 7mg/kg, 8mg/kg, 20 mg/kg, 40mg/kg or 80mg/kg.

3. A method according to claim 1 or 2, wherein the cancer is selected from pancreatic cancer, oesophageal cancer, colon cancer, bowel cancer, prostate cancer, ovarian cancer, stomach cancer, breast cancer, malignant melanoma or lung cancer.

4. A method according to claim 3, wherein the cancer is pancreatic cancer, colon

15 cancer or ovarian cancer.

5. A method according to claim 3, wherein the cancer is pancreatic cancer.

6. A method according to any one of claims 1 to 5, wherein chymotrypsinogen and trypsinogen is administered in a weight ratio in the range of between about 4 : 1 to 8 : 1, between about 5 : 1 to

7 : 1, or at about 6 : 1.

20 7. Use of chymotrypsinogen and trypsinogen in the manufacture of a medicament for the treatment of cancer, wherein the medicament is administered at a dose of chymotrypsinogen in an amount of equal to, or greater than, 3.5mg/kg and trypsinogen in an amount of equal to, or greater than, 0.6 mg/kg.

8. Use according to claim 7, wherein the medicament is administered at a dose of

25 chymotrypsinogen in an amount equal to, or greater than about 10mg/kg, 20mg/kg or 40 mg/kg, 45 mg/kg, 13 5mg/kg, 250 mg/kg or 500 mg/kg; and at a dose of trypsinogen in an amount equal to, or greater than about 1.5 mg/kg, 3 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 20 mg/kg, 40 mg/kg or 80 mg/kg.

1002957667

2016353539 25 Mar 2020

9. A composition for treating cancer in a subject comprising chymotrypsinogen and trypsinogen wherein the weight ratio of chymotrypsinogen : trypsinogen is greater than 8:1.

10. A composition according to claim 9, wherein the weight ratio is greater than 10:1.

5

11. A composition according to claim 9, wherein the weight ratio is 10:1.

12. A composition according to any one of claims 9 to 11, wherein the composition does not contain amylase.

13. A method of treating cancer in a subject comprising administering chymotrypsinogen and trypsinogen, wherein the weight ratio of chymotrypsinogen :

I0 trypsinogen is greater than 8:1, thereby treating cancer in the subject.

14. A method according to claim 13, wherein the weight ratio is greater than 10:1.

15. A method according to claim 13, the weight ratio is 10:1.

16. A method according to any one of claims 13 to 15, wherein the method does not comprise the administration of amylase.

15

17. Use of chymotrypsinogen and trypsinogen, in the manufacture of a medicament for the treatment of cancer, wherein the weight ratio of chymotrypsinogen : trypsinogen in the medicament is greater than 8:1.

18. Use according to claim 17, wherein the weight ratio is greater than 10:1.

19. Use according to claim 18, wherein the weight ratio is 10:1.

20 20. Use according to any one of claims 17 to 19, wherein the medicament does not comprise amylase.

21. A method or use according to any one of claims 13 to 20, wherein the cancer is any one of pancreatic cancer, oesophageal cancer, colon cancer, bowel cancer, prostate cancer, ovarian cancer, stomach cancer, breast cancer, liver cancer, malignant 25 melanoma, fibrosarcoma or lung cancer.